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ABSTRACT 
 Direct post-translational control over a protein of interest (POI) can be exploited 
by manipulating the cells protein quality-control systems responsible for either 
intracellular turnover through ubiquitination (POI half-life) or repairing and degrading 
misfolded proteins.1 In an effort to target and degrade a high value POI we selected the 
enzyme human thymidylate synthase (TS) for post-translational degradation through 
ligand-directed ubiquitination and hydrophobic tagging.  
 Thymidylate synthase catalyzes the reductive methylation of 2’-deoxyuridine 
monophosphate (dUMP) to 2’-deoxythymidine monophosphate (dTMP). As the de novo 
source of dTMP the regulation of intracellular TS is strictly controlled by ubiquitin-
independent proteasomal degradation mediated by an internal TS-degron sequence.2,3 
Using conventional peptide synthesis and the TS-directed antifolate, raltitrexed (RTX), 
we designed a series of a high affinity RTX-directed conjugates that specifically recruited 
TS to the von Hippel Linadau (VHL) E3 ligase in order to facilitate ubiquitin-dependent 
proteasomal degradation. These protein suppression conjugates are known as 
PROteolysis TArgeting Chimera’s (PROTAC). These conjugates were challenged against 
TS and TS overexpressing cell lines with their inhibition and ubiquitination events 
monitored by half-life and Western blot analyses. However, no evidence of ubiquitin-
mediated proteasomal degradation was found.  
vii  
 Contrary to the reliance of ubiquitination by the PROTAC’s system, we sought to 
simplify our approach and “tag” TS with a hydrophobic probe. The seminal driving force 
behind protein folding and stabilization is the burial of core hydrophobic residues.4 While 
these residues are critical to maintaining the native folding state, partial denaturation 
results in their exposure, leading to incomplete folding events and proteasomal 
degradation.5,6 In an effort to mimic this endogenous event and promote active TS 
proteasomal degradation, we generated a small library of RTX linked hydrophobic tags 
using the Kenner safety-catch handle under solid phase peptide synthesis. In this study 
we found that the general length of both the linkage and surface area of the hydrophobic 
tag were essential to growth inhibition of TS bearing cells. The implications of these 
findings, with regards to both the synthetic endeavors and their respective biological 
results, are discussed.  
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CHAPTER 1 
 INTRODUCTION 
 
1.0 THYMIDYLATE SYNTHASE: FUNCTION AND MECHANISIM  
Since the early 90’s human thymidylate synthase (hTS) [EC 2.1.1.45] has been a 
high profile drug target for colorectal cancer.7 A concerted effort has been made to 
delineate the relationship between its structural biology and pharmacological potential, as 
hTS is responsible for the de novo production of thymidine, a process which is invariably 
highjacked by malignant cells and other tissue specific neoplasms. Through the tandem 
coupling of the nucleoside 2’-deoxyuridine monophosphate (dUMP) and the cofactor 
N5,N10-methylenetetrahydrofolate (CH2H4PteGlu), hTS catalyzes the reductive 
methylation of dUMP to produce one of the four nucleoside-phosphates necessary for 
genetic inheritance: 2’-thymidine monophosphate (dTMP) (Figure 1.1).  
 The highly evolutionary conserved human thymidylate synthase is a 70 kDa 
committed dimer complex with each monomer (35 kDa) interface consisting of an 
extremely tight interaction between each of the two six-stranded β-sheets - one from each 
subunit.8 The back walls of each active site, where the catalytic cysteine resides, sit at the 
surface opposite of the β-sheet interface.8 Each catalytic cysteine occupies position 195 
(Cys198 in E.coli) at the base of the fourth β-strand in the catalytic loop 181-197. Crystal 
structures have shown the catalytic loop placing Cys195 outside the active site,
2  
 
 
Figure 1.1. A Representative schematic for the synthesis of deoxythymidine 
monophosphate (dTMP) from deoxyuridine monophosphate (dUMP) by hTS. The 
metabolic turnover of dUMP coupled with its cofactor, N5,N10-
methylenetetrahydrofolate (CH2H4PteGlu), to produce dTMP and dihydrofolate 
(H2PteGlu), which is subsequently reduced by NADPH through dihydrofolate 
reductase (DHFR). Its product, tetrahydrofolate (H4PteGlu) is used to regenerate 
CH2H4PteGlu through a reaction with the PLP-dependent enzyme serine 
hydroxymethyltransferase (SHMT) and the amino acid L-serine. 
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indicating that the conformer is inactive. In concert with this inactive conformation was 
the disordered state of loop 108-129, which is perpendicular to the catalytic loop 181-
197.8 Conversely, upon ligand binding, loop 181-197 is rotated 180° toward the active 
site pocket and inserts the nucleophilic Cys195 residue with a concomitant ordering of 
loop 108-129 (Figure 1.2).9 The order and mobility of the two loops work in concert to 
foment the catalytic turnover of dUMP. In between this dynamic mobility hTS forms an 
asymmetrical alignment, which is believed to act as a guide for both substrates and assist 
in docking with in the active site.  
This shift in conformation subsequently renders the opposite monomer unit 
incapable of binding substrates, hence, the binding of substrates to hTS creates a dynamic 
active/inactive population. In another word, the concerted order (or disorder) of loops 
181-197 and 108-129 renders each monomer as active or inactive.10 Post-substrate 
binding, a significant structural adjustment occurs where specific active site residues are 
repositioned toward the incoming ligands. The ordered sequential manner in which the 
substrates bind relies upon the pyrimidine dUMP binding first, followed by the cofactor, 
CH2H4PteGlu. Once the substrate and co-substrate are bound, hTS catalyzes the reductive 
methylation of dUMP followed by the sequential release of H2PteGlu and the product, 
dTMP (Figure 1.3). 
 Interestingly, hTS catalyzes the first step in the cyclic process devoted to the 
transfer of single carbon moieties, which are found under three different oxidation states 
of CH2H4PteGlu: formate, formaldehyde, and methanol. The transfer at the formaldehyde 
oxidation state, which is equivalent to the transfer of a hydroxymethyl group, is catalyzed 
by hTS as CH2H4PteGlu is in the correct oxidation state to transfer a hydroxymethyl  
4  
 
 
Figure 1.2. Active conformation of thymidylate synthase monomer (PDB 1HYV). The 
four β-strands (yellow) generate a tight interface between monomer units. At the top 
of the first β-strand resides the catalytically active Cys195, which is currently 
positioned in the active state with both loops, 181-197 (red) and 108-127 (blue) 
occupying the same active conformation.9  
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Figure 1.3. A pseudo-Cleland diagram illustrating the sequential ordered binding and 
release of dUMP/CH2H4-PteGlu followed by H2-PteGlu/dTMP, respectively. (E 
represents human thymidylate synthase). 
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group (originally from L-serine). Here hTS catalyzes the transfer of the single carbon unit 
and a lone hydride from different sites of the cofactor CH2H4PteGlu. However, the final 
product is methylated rather than hydroxymethylated, corresponding to a reduction of 
dTMP and the subsequent oxidation of CH2H4PteGlu to H2PteGlu. The mechanistic 
process is achieved through the dynamic alignment and realignment of the substrate and 
co-substrate throughout a series of steps in the catalytic domain of hTS (Figure 1.4).   
The steps demonstrating the mechanistic anatomy of TS were realized upon the 
investigative efforts surrounding the 25 conserved residues within the active site.11 
Contrary to the premise of nature conserving residues across multiple species, it was 
determined that only five residues proved to be irreplaceable: Arg218 (dUMP 
stabilization), Asp221 (cofactor stabilization), Cys198 (nucleophile in Michael Addition 
to C6 of dUMP, intermediate I), Tyr146 (active base that abstracts C5 proton from 
intermediate III), and Glu60 (cofactor elimination from ternary complex).11 The 
guanidinium groups of four conserved arginine’s produce an electrostatic anchor that 
surrounds the phosphate of dUMP in a tetrahedral arrangement, securing dUMP for the 
impending arrival of the cofactor.11 In addition to stabilizing dUMP, Arg218 acts as a 
physical “buttress” through the hydrogen bonds between its guanidinium head group and 
two loops within the active site.  
Formation of the ternary complex is accomplished upon cofactor binding, which 
causes a conformational shift, directing segments of the primary structure to form the 
core of the active catalytic binding site around the reactants through maximizing 
hydrophobic interactions and sequestering the substrates from the bulk solvent.11 Hence,
  
7 
Figure 1.4. The catalytic mechanism for the reductive methylation of dUMP by hTS with the cofactor CH2H4PteGlu. (I) Cys195 
covalently activates C6 of dUMP by nucleophilic Michael addition with concomitant ring-opening formation of the iminum at N5 of 
the pterin ring. (II) Upon formation of the iminum ion, the enolate attacks the resulting Mannich base generating the covalent linkage 
between the two substrates. (III) Tyr146 abstracts the C5 proton on dUMP reconstituting the active enolate. (IV) The enolate 
subsequently collapses eliminating the covalent bridge and transferring the methylene moiety to C5. (V) Finally, a hydride-transfer 
from C6 of the pterin ring reforms the C5-C6 unsaturation, releasing Cys195 and forming dTMP.1  
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the binding cavity isn’t fully formed until (i) dUMP is sequestered, (ii) a number of 
hydrophobic side chains are within van der Waals contact with either the pterin ring 
system (2-aminopteridin-4(3H)-one) or p-aminobenzylic acid/thiophene substituent of the 
cofactor, (iii) electrostatic side chains or water-mediated hydrogen bond network has 
coordinated with the cofactors glutamate(s), and (iv) Asp221 has coordinated with the 
pterin ring and additional hydrogen bonds through amino acid side chains and water.11 
The conserved binding mechanism, in which TS successfully mediates a convoluted 
reaction coordinate, is paid through an entropic reduction mediated by cofactor binding 
and its effects upon closing the active site, aligning the reactants, and solvent 
sequestration.11  
 
1.1 ANTIMETABOLITES OF THYMIDYLATE SYNTHASE  
 Antimetabolites are currently the most widely applied treatment for both viral 
infections and cancer therapies. In general, they [antimetabolites] are analogs of natural 
metabolites that either directly or indirectly play a role in the metabolism or biosynthesis 
of DNA and RNA.12 Antimetabolites are of strategic importance regarding their 
applications in cancer. This is due to the unmitigated proliferation that many cancers 
exhibit in order to maintain their rapid and incongruous expansion.  
As a malignancy develops, it requires a vast carriage of nutrients and a steady 
source of carbon. In order to maintain this rate of expansion, cells located in the tumor 
parenchyma establish aberrant vasculature networks, which act as industrial highways for 
the import of carbon.13 The dramatic intake is complemented by increased DNA 
  9 
synthesis and replication, cell division, and overall tumor survival. Progression of tumor 
growth correlates to altered genetic expression and gene-product production, a process 
that is intrinsically relevant to the metabolic fate of folic acid and the genes encoding 
their respective binding and import proteins.14 As the centerpiece in DNA/RNA 
biosynthesis and repair, folic acid is an essential cofactor as demonstrated by its 
supplementation for expecting mothers and its routine use as an antifolate in oncology 
clinics.  
Dietary folic acid is chiefly found in leafy green vegetables, fruits, legumes, and 
liver. Upon ingestion, folic acid primarily accumulates in the intestine with adsorption 
occurring in the jejunum. Here they are transferred across the apical membrane, as well 
as in the kidneys, and released into circulation as 5-methyl tetrahydrofolate (5mTHF).15 
The cellular acquisition of 5mTHF allows for the metabolic methylation of homocysteine 
to produce methionine and H4PteGlu (THF).  The cofactor THF is the responsible unit for 
the one carbon donation in biosynthesis of the nucleoside dTMP.15 
Of consideration to this research are the pyrimidine and folate (Vitamin B9) 
analogs, which suppress the catalytic capacity of thymidylate synthase – the de novo 
source of thymidine. In the absence of dTMP, inhibition of hTS leads to a reduction in 
the intracellular thymidine pools disrupting DNA synthesis and leads to cell death – a 
phenomenon known as ‘thymineless death.’16 This metabolic bottleneck represents a 
prime opportunity for the development for chemotherapeutics directed at inactivating 
hTS.  Clinically, the most widely used anti-TS agent is the suicide inhibitor 5-fluorouracil 
(5FU). It’s clinical presence was based on the observation that uracil metabolism was 
used more widely in tumors than normal tissues, strongly indicating a potential 
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therapeutic opportunity.17 Post-systemic delivery, 5FU is anabolized as a pro-drug to its 
active form 5-fluoro-2’-deoxyuridylate (FdUMP) within the cell. Here, FdUMP’s 
cytotoxicity is realized by the irreversible ternary complex that forms upon is binding to 
hTS. The inhibition of hTS depletes the dTMP pools and induces severe destabilization 
of the other three deoxynucleotide pools through separate feedback controls.18 
Ultimately, this perturbation fractures DNA synthesis and repair, allowing the cell to 
initiate apoptotic events.   
Consequently, the blockade induced by FdUMP also leads to increased levels of 
dUMP’s precursor metabolite: dUTP. Both the 5FU intermediate FdUTP and dUTP can 
be incorporated into DNA causing strand breaks while maintaining a relative “immunity” 
from the action of nucleotide excision repair by uracil-DNA-glycosylase (UGD).18 While 
it appears that FdUMP possesses more than one mechanism to halt hTS turnover, 
thymidylate kinase can salvage resident thymidine pools through phosphorylation to 
reinstate dTMP, thus circumnavigating any intracellular depletion or inactivated hTS and 
yielding a mechanism of resistance.  
The over all response rates under the administration of single anticancer agent are 
typically low and, in colorectal cancer (CRC), are approximately 10-15% with 5FU.19 
Combining therapies to increase the therapeutic response to CRC and surpass potential 
routes of resistance has dramatically improved 5FU’s intrinsic value. Specifically, the use 
of antifolates has compounded the efficacy of 5FU’s and as a result it has maintained its 
clinical presence from the late 1950’s. The cooperatively displayed by co-administration 
of antifolates and 5FU lies within the cells requirement to maintain high endogenous 
levels of reduced folate (CH2H4PteGlu). In order to maintain optimal binding conditions 
  11 
of FdUMP to hTS the antifolate Leucovorin (LV, 5’-formyltetrahydrofolate) was 
administered to supplement the intracellular expansion of reduced folate. Uptake of LV is 
mediated by the reduced folate carrier (RFC) and is then subsequently (poly)glutamylated 
by folylpolyglutamate synthetase (FPGS). This enzyme, FPGS, affixes multiple glutamic 
acid residues to the gamma-carboxylate of LV, which serves to increase the solubility of 
LV and prevent premature export.20 Moreover, the addition of glutamic acid residues to 
LV, and other notable reduced folate analogs, enhances the stability of the 
hTSFdUMPLV complex. It was shown in large meta-analyses of CRC that while the 
LV/FdUMP co-administration generated excellent response rates, this didn’t translate in 
any significant extension of survival.21  
 In order to circumvent the deleterious effects of fluoro-pyrimidine resistance, 
alternate hTS-targeting strategies were developed and focused on TS cofactor analogs. 
Structural analogs of CH2H4PteGlu were designed around modification of the pterin ring 
system, the number of methylene spacers between the ring system and the central 
aromatic unit, and to a lesser extent, the modification of the terminal glutamic acid 
moiety (Figure 1.5).  
Raltitrexed (RTX, Tomudex or ZD1694) is a specific quinazolinone inhibitor of 
hTS that demonstrated high affinity for hTS and improved cellular retention in addition 
to low off-target activity when compared to its hTS analog counterparts (Figure 1.5). 
Clinically, RTX showed promising results against breast, pancreas, hepatic, gastric, and 
CRC with response rates ranging from 14-30%.22 Curiously, as a single therapeutic in a 
CRC trial, RTX yielded a slightly lower median survival when compared to 5FU despite
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Figure 1.5. Antifolate inhibitors of thymidylate synthase and their respective half-
maximal inhibitory concentrations (R = Glutamic Acid). 
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producing a superior toxicity profile.23 Nonetheless, as of the fall of 2014 there five 
active clinical trials registered with the clinical trials database, Clincialtrials.gov, all of 
which pair the co-adminstration of RTX with taxanes, platins, and radiation therapy or a 
combination of angiogenic inhibitors, platins, and 5FU.  
Raltitrexed was closely modeled after CB3717. Despite holding great promise as 
an hTS inhibitor, CB3717 demonstrated life-threatening nephro and dose-limiting hepatic 
toxicity, prematurely terminating its clinical development.20 Synthetic alterations of 
CB3717 resulted in the rational design of RTX, which formed the ternary complex 
hTSFdUMPRTX (Figure 1.6). Modifications of CB3717 included replacing the 2’-
amino group on the pterin ring, the methylenepropargyl at N10, and the benzene ring 
system with two methyl groups and thiophene moiety, respectively (Table 1.1) These 
modifications altered the compounds partition coefficient, which improve aqueous 
solubility and reduced it to a benign nephrotoxicity profile. As with CB3717, RTX is a 
structural analog of CH2H4PteGlu, but it lacks the key methylene moiety involved in 
dTMP synthesis and therefore, it cannot participate in DNA synthesis or in its inhibitory 
action, which is dependent upon dUMP accumulation.20  
Raltitrexed is transported into the cell through the RFC as shown by its resistance 
to enter cells (cell line L1210:1565) with impaired RFC function. Once inside the cell 
RTX undergoes γ-polyglutamylation processing by FPGS where glutamic acid residues 
are sequentially ligated via γ-linkages to the gamma-carboxylate of RTX. Against cell 
lines unable to polyglutamylate reduced folates, the IC50 of RTX increased from 0.009 to 
>100 µM, demonstrating the synergistic relationship between γ-polyglutamylation and
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Figure 1.6. Ternary structure of Thymidylate synthase monomer (PDB 1HYV), RTX, 
and dUMP. At the base of the binding pocket, C6 of dUMP is covalently attached to 
the sulfhydryl of Cys195 (magenta). Directly above dUMP is the planar face of the 
quinazolinone ring system of RTX, which sits directly above and offset of the 
nucleosides ribose. The thiophene and glutamic acid moiety of RTX are rotated 90° 
with respect to the quinazolinone and 45° into the plane of the crystal structure. The 
catalytic loop (residues 181-197) is in red.9 
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ID 
C2 C7 N10 Aryl 
Group 
Growth Inhibition, IC50 (µM) 
R1 R2 R3 L1210 
L1210:1565 
(RFCneg) 
L1210:MB3 
(FPGSneg) 
        
RTX CH3 H CH3 Thiophene 0.009 0.92 70 
2-NH2 NH2 H CH2 Thiophene 0.72 0.5 94 
7-CH3 CH3 CH3 CH3 Thiophene 1.6 43 9 
        
ICI 198583 CH3 H PgA Benzene 0.13 8 2.7 
CB3717 NH2 H PgA Benzene 5.5 5.5 13 
7-CH3 CH3 CH3 PgA Benzene 0.2 8 0.6 
Table 1.1. Relationship between the structural substitutions in raltitrexed and their 
corresponding effects upon cellular uptake by the RFC and polyglutamylation as 
measured by growth inhibitory properties compared to ICI 198583 and CB3717.  
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antifolate potency.24 Notably, it was determined that within a 30-minute window roughly 
90% of the drug was in mono-triglutamate form.  After 24-hours only 30% of the tritiated 
material was lost with the remaining consisting of tetra, penta, and hexaglutamate 
forms.20 This concludes that the rate of FPGS processing is faster than rate of RTX export 
and it estimates that the number of γ-glutamate associated with RTX is determining factor 
in prolonging drug sequestration. It was noted that if the cells were resuspended in fresh, 
drug-free media for 4 hours after the 24-hour incubation period that 40% of TS activity 
returned. This may be interpreted in two ways: (a) the FPGS process was retarded, thus 
the rate of processing was slowed; and (b) that although the γ-polyglutamate forms of 
RTX enable cellular retention, constant drug exposure may be required.20 Nonetheless, 
the mixed noncompetitive inhibition exhibited by RTX sees a dramatic improvement in 
inhibitory potency (hTS affinity) with the addition of each corresponding γ-
glutamylation.  
The therapeutic value of RTX lies in its ability to maintain an intracellular 
presence, thus increasing tissue residency. The result of which has been attributed to the 
4-7 γ-connected glutamic acid residues to RTX.  Using ecTS (E. coli Thymidylate 
Synthase) and a tetraglutamate analog of CB3717 Kamb et al. showed that 
polyglutamylation alters the kinetics of ligand binding through minimal hydrogen 
bonding and van der Waals contacts; although the majority of these contacts were 
devoted to Glu-1 (glutamic acid) via a water-mediated hydrogen bond network to ecTS. 
Both Glu-2 and Glu-3 (Glu-4 density was ambiguous) were found to be loosely fit, 
suggesting that the γ-polyglutamyl tail is largely mobile and didn’t rely on any specific 
ligand-protein interaction.25 This is likely due to the random-coil formation that 
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polyglutamate peptides adopt at physiological pH.  Therefore, a high entropic threshold is 
likely pronounced during the formation of the ternary complex. Interestingly, the overall 
fold improvement regarding the number of glutamic acid residues added with respect to 
TS inhibition were found to vary between species.25 
 
1.2 UBIQUITIN-INDEPENDENT PROTEOSOMAL DEGRADATION  
 The homeostasis of intracellular protein levels is primarily maintained by the 
proteasome. Located in both the cytosol and the nucleus, the proteasome acts as a 
disposal system responsible for destroying unwanted, aged, over saturated, and misfolded 
proteins that, if left unregulated, would generate a toxic cellular environment.  However, 
its spatial and temporal control of key cellular cycles and regulatory system substrates is 
its prime directive. Hence, cell division, environmental stress response, and apoptosis are, 
in part, under the direction of the proteasome. Although the physical function of the 
proteasome is proteolysis, it is a member of a much more complex and diverse system of 
protein quality assurance.  
It’s generally assumed that substrates are polyubiquitylated, via the covalent 
linkage to ε-amino group of the substrates lysine, through a series of enzymes-complexes 
that ultimately designate proteins for direct degradation (Figure 1.7). The proteasome-
ubiquitin system (UPS) possesses an additional layer of organizational molecular-
recognition systems that are independent of degradation. Monoubiquitylation, for 
example, is necessary for the trafficking of proteins, receptor internalization, virus
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Figure 1.7 General mechanism for ubiquitin-dependent proteasomal degradation. The 
first step involves the E1 enzyme, Ube1, activation (via ATP) of ubiquitin (Ub) 
through the conjugation of a free cysteine on E1 and the carboxy terminus of Ub. 
Once activated, one of the 30-members of the E2 enzyme family can either directly 
transfer the Ub unit to the protein of interest (POI) or interact with one of the 700 
substrate-specific E3 ligases through two avenues: (i) the E3 ligase can directly 
conjugate to the activated Ub and ubiquitinate the POI, (ii) the E3 ligase can form a 
complex with E2-Ub where it facilitates the transfer of Ub from E2 unit to the POI.  
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budding, and histone modification.26-29 Moreover, the ubiquitin-proteasome relationship 
may also require adaptor proteins or molecular chaperones in order to corroborate 
substrate identity as post-translational modifications substantially alter the proteome’s 
diversity.30  
Contrary to ubiquitin-dependent proteasomal degradation pathway(s) there exists 
a small population of protein substrates that undergo proteasome recognition, but without 
involvement of the complex network of activating and ligating enzymes. This subset of 
degradation targets is independent of ubiquitin conjugation and therefore undergoes 
ubiquitin-independent proteasomal degradation. Thymidylate synthase (TS) is a non-
ubiquinated proteasomal substrate that falls directly into the same aforementioned 
category as Ornithine decarboxylase (ODC), calmodulin, p53 tumor suppressor protein, 
and the CDK inhibitor p21Cip1.31-34  
In an unbound state the half-life of hTS is approximately 6-10 hours.  However, 
inhibitors such as FdUMP and RTX stabilize the ternary complex and extend the 
enzyme’s half-life to 20-24 hours, presumably altering the proteasome’s capacity to 
degrade TS. This phenomenon was initially attributed as the result in an autoregulatory 
response mechanism due to the exposure of the previously mentioned TS inhibitors. It 
was postulated that exposure to TS inhibitors resulted in a 2-4 fold induction of enzyme 
as a result of disrupting hTS-mRNA complex, thus blocking translational repression and 
facilitating translational progress presenting a mechanism of resistance.35 It was found 
that fluoropyrimidines do not alter ribosome binding to TS mRNA.  Nor did altering the 
binding domain of mRNA for the ribosome affect induction of TS.36  
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The particular structural features of the N-terminus of TS, which is extended in 
mammalian TS, appeared to regulate the enzymes intracellular half-life through 
ubiquitin-independent proteasome degradation with 26S regulatory complex.37 Further 
investigation confirmed the ubiquitin-independent proteolysis of the TS polypeptide 
through site-directed modification of all internal lysine’s generating a ‘lysineless’ TS via 
a K→R modification.  
Under the lysineless mutant, administration of FdUMP still yielded an inhibitory 
ternary-complex, thus the catalytic activity of TS was retained; additional evidence of its 
ubiquitin-independence was corroborated under proteasomal inhibitors where the wtTS 
half-life was restored upon their administration.38 Structurally, the intrinsically disordered 
region (IDR) of the N-terminus is comprised of 45 residues possessing a proline-rich 
region spanning positions 9-15 (9PRRPLPP15) and 24-27 with two-conserved arginine’s 
at positions 10-11. Downstream of the flexible domain is a highly conserved amphipathic 
15-residue α-helix (hA) from residues 31-45. Although hA functions as a structural 
scaffolding in tandem with the IDR rather than in a sequence specific manner.39 
Together, these 45 residues function as an independent degradation signal or degron 
sequence.2  
Although the domain is highly disordered, and therefore not found in crystal 
structures, deletion of the degron sequence does not abrogate its catalytic activity, but 
instead stabilizes the enzyme. Certain residues were found to possess critical features that 
supported its ability to act as a degradation signal. Located at the penultimate position of 
the N-terminal polypeptide lays a proline, which with the exception of M. musculus, is 
conserved in mammals, and whose substitution only serves to stabilize TS (except under 
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Pro2→Gly2 or Pro2→Val2 point mutations).  Hence, the degron sequence requires 
proline in the second position, and to a lesser extent, valine or glycine.3 TS also 
undergoes post-translational excision of the Met initiator, but doesn’t experience N-α-
acetylation (it’s noted that acetylation of the N-terminal residue inhibits ubiquitylation 
and thus, proteasomal degradation40-42) of the N-terminal amino acid leaving Pro2 free. 
Conversely, Pro2→Leu2 or Pro2→Ala2 substitutions promote acetylation and stabilize 
the TS polypeptide. This strongly suggests that the absence of acetylation and the 
presence of proline at the penultimate position are critical to the intracellular half-life of 
TS.3  
Further evidence of the critical nature of the arginine dipeptide was demonstrated 
through the half-life analyses of phylogenically related TS. Lacking this motif, arginine 
point mutations were introduced to the N-terminus of cow, rabbit, platypus, and 
armadillo TS where they demonstrably converted the N-termini of non-primate TS into 
active degrons.  Thus, the absence of the Arg-Arg motif is responsible TS stability in 
these species.2 Taken together, the hTS degron functions as a bipartite degradation 
system composed of two domains within the N-terminus: the IDR, which possesses the 
critical residues Pro2 and 9-15 (9PRRPLPP15), along with the preceding α-helix. Both 
domains are required and are the key determinants in the post-association steps leading to 
the ubiquitin independent proteasomal processing of hTS.43 
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1.3 TARGETING AND HYDROPHOBIC TAGGING OF CELLULAR PROTEINS  
As with any intracellular regulatory system, its spatial and temporal control can 
be subjected to ‘reprogramming’ through tumorigenesis. Of particular interest are the 
established systems that manage protein turnover in order to maintain a healthy proteome 
and modulate protein homeostasis. The strict regulation of protein turnover is typically 
mediated by the proteasome and its ancillary system of substrate-specific ligases and 
ubiquitin-conjugation enzymes colloquially referred to as the Ubiquitin-Proteasome 
System (UPS).  
The UPS asserts posttranslational control through four distinct mechanisms: (i) 
activation of ubiquitin in an ATP-dependent reaction to the ubiquitin-activation enzyme 
(E1), (ii) conjugation (or transfer) of ubiquitin to the ubiquitin-conjugation enzyme (E2) 
from E1, (iii) ligation of ubiquitin to the substrate-specific ligase (E3) from E2 with 
concomitant identification of the substrate by the E3 ligase, and lastly (iv) translocation 
and proteolysis of the substrate via the proteasome. This indispensable identification and 
degradation system governs cell cycle progression, apoptosis, DNA double-strand repair, 
and angiogenesis, which are, notably the primary systems which cancer appropriates to 
modulate its own malignant proliferation.44-48  
Reports correlating cancer and the involvement of the E1 and E2 enzymes are 
sparse.  However, a large body of research has clearly linked the deregulation of the E3 
ligases to multiple forms of disease and cancer.49-52 Checkpoint activation, cell-cycle 
progression, and apoptosis are all potential points of oncogenic manipulation where the 
E3-Ub machinery is readily commandeered, making it a therapeutic target.53, 54 An E3 
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ligase of particular interest is the modular Skp-Cullin-F-box (SCF) or SCF complex. This 
Ub-E3 ligase is composed of a heterotetrameric complex consisting of a Cullin subunit 
Cul1, which forms a u-shaped complex that simultaneously interacts at its N-terminus 
with the adaptor protein Skp1 (S-phase-kinase-associated protein-1), and its C-terminus 
with the Rbx1: an ancillary zinc-binding RING finger where the E2 conjugating enzyme 
docks. The final component, the F-box, is tethered to Skp1 and functions as an adaptor 
protein where it recruits the POI and supply’s substrate specificity.55  
Asserting control over the SCF complex via external tunable pharmacological 
agents has provided a unique opportunity to control protein function through these 
external posttranslational modifications. This technology has been developed by a 
number of investigators. Crews et al. have pioneered some of the more simplistic and 
facile protein degradation technologies.56-59 Using the SCF complex with the mammalian 
F box protein (FBP) β-TRCP/E3RS (SCFβ-TRCP), they were able to target and promote 
Ub-directed degradation of an off target POI: methionine aminopeptidease-2 (MetAP-2) 
[60].  
This was accomplished due to the intrinsic capability of SCFβ-TRCP to identify a 
10-residue amino acid signal located on IκBα, a negative regulator of the transcriptional 
modulator NFκB. Upon environmental inflammation, SCFβ-TRCP promotes Ub-directed 
degradation of IκBα, thus activating NFκB.61 The inflammatory response induces 
IκBα kinase (IKK) to phosphorylate both serines within the 10-mer-signal peptide of 
IκBα , thus promoting its [phosphorylated IκBα] complexation with β-TRCP.62-64  
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The IκBa  phophopeptide (IPP) can be used recruit β-TRCP to the SCFβ-TRCP 
complex. To determine if the SCFβ-TRCP complex could successfully target and degrade 
MetAP-2, a high affinity MetAP-2 covalent inhibitor, ovalicin (OVA), was connected to 
IκBα, generating a bifunctional targeting system termed proteolysis-targeting chimeric 
system (PROTAC-1). This system demonstrated the direct ubiquitination and degradation 
of a foreign substrate, MetAP-2, through the chemical control of the endogenous E3-
ligase SCF system.65 The PROTAC itself was the result of the facile linkage of the 
angiogenic MetAP-2 inhibitor OVA to the IκBα peptide via the commercially available 
disuccinimidyl suberate-glycine linker using standard FMOC chemistry.  
This strategy has provided an alternative technique to interrogate the inner space 
of proteome without resorting to the more quixotic mutational or targeted screens used to 
generate a specific phenotype. The PRTOAC posttranslational technology has seen 
further applications to knock down both the androgen and estrogen receptors using the 
IκBα-estradiol and IκBα-dihydroxytestosterone PROTACT-2 and PROTAC-3, 
respectively, with the SCFβ-TRCP complex.66  
Alternative E3 domains have also been successfully employed, such as the von 
Hippel-Lindau (VHL) tumor suppressor E3-Ligase, which recognizes the central 
hydroxylated proline of the seven amino acid sequence: -ALAPYIP- of hypoxia inducible 
factor 1α (HIF1α). Under normoxic conditions a proline hydroxylase (PHD) catalyzes 
the hydroxylation of the central proline in the aforementioned seven-mer of HIF1α. The 
VHL recognizes the modification and constitutively ubiquinates HIF1α until cellular 
conditions shift to hypoxic levels where the transcription factor is freed and mobilizes 
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downstream system necessary for cell survival.67 Similar to the SCF complex, the VHL 
has also seen use in the knockdown of the steroid hormone receptor using PROTACs 
constructed of DHT and estradiol with the hydroxylated HIF1α peptide LAPYI.68 
Treatment of breast ERα-dependent breast cancer cells and androgen dependent prostate 
cancer cells with these PROTACs, respectively, resulted in cell cycle arrest, inhibiting 
the proliferation of both cells lines.68 
Although the PROTAC approach provides a novel and robust system for 
posttranscriptional control, its limitations are easily realized when comparing the 
potential number of therapeutic targets to readily available ligands directed at disease-
causing substrates, oncogenic products, or pathogens.69 Hence, the ability to regulate a 
specific member of the proteome through a global application will require the 
appropriation of a quality control system inherent to living systems.  
Currently, there are methods that target specific proteins for degradation in the 
absence of a direct targeting ligand: (i) in Arabidopsis thaliana the hormone auxin can be 
used to dimerize a SCFTIR1 complex to an AXR3 transcriptional repressor. When the 
repressor is genetically fused to a POI the E3-ligase can promote proteolysis of the fusion 
construct.70 (ii) To induce GFP targeted degradation a chimeric FBP from Slmb (a 
Drosophila melanogaster FBP) was engineered by fusing the N-terminal of Slmb to a 
single-domain antibody (VhhGFP4), which is directed to GFP, YFP, or eYFP.71 This 
SCFSlmb-VhhGFP4 fusion E3-ligase targeted GPF constructs in drosophila embryos and was 
not only readily accessible to the UPS, but devoid of any deleterious effects upon the 
embryos. Interestingly, this method demonstrated the ability to rapidly phenocopy loss-
of-function mutations on both cytoplasmic and nuclear proteins.71  
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The systems mentioned above necessitate genetic modification to generate a 
fusion system capable of targeting a POI. Although such systems remain relevant to the 
exploration of protiec structure-function relationships, they don’t address the need to 
capture more of the ‘undruggable’ portion of the proteome. To address this, a general 
method that utilizes small molecules capable of targeting proteins in the cellular milieu is 
necessary. Specifically, this method should examine a quality control system that is 
fundamental to the intrinsic nature of all proteins.  
This characteristic is apparent within the core of a protein’s tertiary structure, 
where the burial of hydrophobic residues generates a cumulative stabilizing force. 
However, partially folded or misfolded protein states can lead to the exposure of 
unstructured hydrophobic regions that would otherwise be buried in their native states. 
These aberrant events can promote aggregation of amorphous aggregates or oligomers in 
a concentration specific manner, which can increase the cellular distribution of unfolded 
endoplasmic reticulum (ER) and cytosolic proteins.  
To protect and sustain protein homeostasis within the cells secretory pathway, the 
ER and Golgi apparatus turn to a sentinel intracellular signaling system that monitors 
folding and unfolding events: the Unfolded Protein Response (UPR) pathway. Here, the 
UPR can coordinate the processing of metastable or misfolded proteins which can be 
reprocessed back into the folding cycle or, if proper folding is not restored, they enter the 
ER-associated degradation (ERAD) pathway, which prepares the substrate for ER-
translocation and ultimately cytosolic proteolysis via the UPS.72, 73 Should an imbalance 
of misfolded proteins continue and overwhelm the ER processing machinery, the UPR 
will modulate three main responses: (i) brief attenuation of global translational output via 
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PERK/eiF2α phosphorylation, (ii) transcriptional activation of ER protein folding 
capacity by up-regulating chaperones and preventing ER-bound mRNA translocation (via 
IRE1) while simultaneously increasing the rate of degradation of misfolded proteins (via 
ERAD), and (iii) in the event where the first two responses are either prolonged or 
disrupted, cell death may be initiated.74, 75  
Externally, as opposed to within the ER landscape, the translational production, of 
nascent polypeptides is also at risk of misfolding and aggregation. To avoid such 
deleterious outcomes and ensure the conformational integrity of proteins and overall 
protein homeostasis (proteostasis), cells invest in a plexus of highly specialized 
eukaryotic chaperones: HSP40, HSP60 (TriC), HSP70s (BiP), HSP90s, and HSP100s.76, 
77 These versatile and structurally unique macromolecules can be mobilized to directly 
recognize and bind hydrophobic moieties in an effort to facilitate proper folding or 
refolding under ribosomal-mediated proteogenesis and stress-inducible scenarios. In 
order to govern a coordinated proteostasis network, synergistic action between multiple 
pathways, such as the UPR of the ER and UPS mediated proteolysis, must be inherent 
(Figure 1.8).  
Manipulation of this protein surveillance system may serve as a potential 
mechanism for therapeutic application. Induction of proteolysis by mimicking protein 
destabilization through hydrophobic exposure may systematically degrade “hydrophobic 
tagged” proteins via the proteasome. Indeed Neklesa et al. have demonstrated the ability 
to impersonate a partially denatured or unfolded state of a protein and its subsequent 
proteolysis using the HaloTag dehalogenase fusion system. By appending a hydrophobic 
adamantane moiety (HyT13) to a haloalkane reactive linker, which possesses high avidity
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Figure 1.8 The integrated proteostasis network comprised (counterclockwise) of the 
trafficking, UPS, remodeling, and aggregation/disaggregation components which 
serve to interrogate and mediate protein fate. Under trafficking, approximately 180 
chaperones and their adaptors contribute to the production of properly folded systems, 
whereas the UPS and autophagy systems possess over 600 and 30 components, 
respectively.   
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for the HaloTag dehalogenase, excellent translational control of various intracellular 
fusion proteins was maintained including transmembrane and zebrafish proteins and 
targeted POI’s in tumor burdened mice.78, 79  
The functional utility of this system was applied to both in vitro and in vivo 
systems targeted against the proto-oncogene, HRAS1, a small GTPase that possess 
elevated tumorigenic potency under the absence of intracellular signaling.80, 81 A key 
diagnostic attribute of the mutant HRAS1G12V allele is that the ectopic expression of this 
gene can produce a transformed phenotype that clearly distinguishes Hras1G12V 
expression. Thus, when Hras1G12V expressing cells are incubated under low serum 
conditions, their ability to maintain cell-to-cell contact is attenuated and they form 
distinct colonies rather than their native monolayer formation.  
Moreover, their [Hras1G12V expressing cells] utility is also realized in 
immunocompromised mice where these cells are capable of tumor formation upon 
systemic administration.82 Suppression of the colony forming capability of Hras1G12V in 
NIH-3T3 was analyzed with a HA-HaloTag-Hras1G12V fusion and a negative control that 
was incapable of binding the haloalkane  (HA-HaloTag-Hras1D106A).  
Upon treatment with the haloalkane-HyT13, the HA-HaloTag-Hras1G12V 
expressing cells had reverted to their native monolayer state, whereas the negative control 
produced distinct colonies indicating that their haloalkane-HyT13 tag had successfully 
eliminated Hras1G12V fusion protein, in vitro. In vivo examination of this system was 
performed in nude mice injected with stably transfected HA-HaloTag-Hras1G12V in NIH-
3T3 cells with concomitant administration of the haloalkane-HyT13. Tumor formation 
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was monitored for 13 days prior to dosing, where members of the treatment group 
reported that the average tumor size was 16% of those in vehicle control group.83 While 
the HaloTag fusion system has clearly shown the ability to induce hydrophobic mediated 
degradation, the system is unable to degrade endogenous proteins unless the HaloTag 
system has been fused to the target protein.83  
Nonetheless, applying this tour-de-force strategy to a system whose degradation 
is mediated by the proteasome, but in an ubiquitin-independent manner, would 
demonstrate the direct applicability of hydrophobic-tagging toward endogenous proteins 
using readily available and modifiable ligands with out a genetically transfected fusion 
construct. 
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CHAPTER 2 
REGIOSELECTIVE MODIFICATION OF RALITREXED  
 
2.0 INTRODUCTION 
 The quinazoline-based antifolate Raltitrexed (RTX, ZD1694) exerts its cytotoxic 
effect upon the enzyme thymidylate synthase (TS, EC 2.1.1.45) by noncovalent 
inhibition, thus preventing dTMP turnover and, ultimately, apoptosis. It was designed to 
be a robust, water-soluble analog of the clinically tested CB3717 antifolate, synthesized 
to encourage polyglutamylation of it’s gamma-carboxylate in order to retain high 
intracellular concentrations and increased cytotoxic potency.1  
Several strategies have been applied to generate polyglutamylate analogs of 
antifolates via solution or solid phase peptide synthesis (SPPS).2-4 Solution phase 
approaches typically necessitate either direct cleavage of the aryl-glutamic acid moiety 
from the pterin ring or employ stereospecific enzymatic cleavage of the parent 
monoglutamate in order to re-conjugate the (poly)glutamyl tail that was retroactively 
synthesized.5, 6  
Conversely, the formation of pyroglutamates and their subsequent mono-, di-, and 
tri(N15)glutamates followed by condensation to the pterin-aryl group has also been 
described for the use as NMR probes.7 Moreover, coupling methods that involved 
DCC/NHS or tertiary amines such as triethylamine or 4-methylmorpholine, proved
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incapable of controlled regioselective amidation and, furthermore, can support 
racemization under conditions for esterification.8-10 The necessity of regioselective 
placement upon antifolate analogs is paramount to their biological activity.11-14 
Alternative approaches that don’t involve the deconstruction of antifolate synthons, yet 
still maintain the regionselectivity required for biological applications, should focus on 
the synthetic modification of the end product of pharmacological agents.15  
Specifically, N-protected glutamic anhydrides have proved useful where their 
formation activates the carboxylate carbonyls toward specific nucleophilic attack. 
Following anhydride formation, activation of the accessible carbonyl is followed by 
nucleophilic addition, thus regioselective opening occurs with concurrent release of the 
newly modified isomer. The resultant regioselectivity will yield a mixture of α and γ 
products that require further isolation and purification.  
Altering the reactions conditions can control regioselectivity of N-protected 
glutamic anhydrides: polar aprotic or nonpolar solvents can favor γ versus α−selectivity, 
respectively, in addition to the steric involvement of both the nucleophile and the N-
associated protecting group.16, 17 The aforementioned routes could easily apply to the 
regioselective modification of RTX without altering the pharmacological activity of the 
antifolate. By selecting the γ-carboxylate of RTX, multiple synthetic alterations could be 
employed. Of specific interest is the facile Cu(I) catalyzed azide-alkyne cycloaddition 
(CuAAC) labeling system. Selectively amidating the γ-carboxylate of RTX with 
propargylamine (PgA) would render the compound receptive to non-fluorogenic azide 
dyes. Upon cycloaddition of the azide-alkyne ligation, the formation of the triazole 
complex would produce a highly fluorescent TS specific probe. Here, we describe the 
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synthetic route to construct a highly specific thymidylate synthase fluorescent probe 
using a known anticancer compound and evaluate its in vitro potential for cellular 
localization of TS.  
 
2.1 RESULTS AND DISCUSSION 
2.1.0 Synthesis and Characterization of RTXγ-PgA by DCC/NHS Coupling 
Initial coupling experiments with 1a and PgA were performed altering between 
EDCI and DCC with NHS coupling in order to trap the γ-carboxylate (Figure 2.1). 
However, this method produced poor regioselectivity and low yields despite DCC-NHS 
stoichiometry. Crude analysis via reverse phase chromatography showed the presence of 
excess dicyclourea (DCU), and confirmed the presence of four products (Figure 2.2). 
Under UV/Vis detection at 341 nm, and confirmed by LC/MS (data not shown), the crude 
material of the DCC/NHS coupling produced four peaks at 1a (23.67 min), 1b (24.69 
min), 1b (24.84 min), and 1d: at (25.77 min), resulting in approximately 75% conversion 
to both alpha (1b) and gamma isomers (1c) in addition to dual α/γ modification (1d). The 
remaining 25% was unreacted starting material (1a) and was recycled for further use 
(Table 2.1). The final α/γ content was 1:1.3 or slightly 50% of biologically active product 
was generated as measured by all observable UV341 peaks. Purification of the conjugates 
was stifled due to the fastidious nature of the acylurea by-product, DCU, necessitating 
multiple injections. Nonetheless, the crude products were separated and purified over a 
reverse phase semi-preparatory HPLC. Each collected fraction was further analyzed via
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Figure 2.1. General synthetic scheme for the pseudo-selective amidation of 1a using 
EDCI and NHS coupling reagents and PgA. Prospective regioselectivities were 
verified by LCMS and yields calculated via UV341. (R = aminopterin-thiophene of 1a)  
 46 
 
 
 
 
  
Figure 2.2 Reverse phase HPLC trace of the crude RTX-PgA conjugates synthesized 
using EDC/NHS. All compounds were monitored at 341 nm. (x-axis in minutes) 
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Table 2.1 Random regioselectivity was demonstrated using DCC/NHS coupling with 
1a and PgA. Multiple substitutions in coupling reagents (DCC/NHS, HOBt/HBTU) 
failed to improve selectivity. 
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LC/MS for their predicted [M+H]+ at 459, 496, and 533 for 1a-d, respectively (data not 
shown). The fractions were then dried and prepped for 1H NMR characterization. In the 
interest of characterization and future scaling, only compounds 1a and  1c were analyzed. 
Key peaks in the structural assignment of 1a were the diasterotopic methylenes at 2.0 and 
2.2 ppm (b,b’) along with 2.4 (a,a’), which were proposed to experience a slight upfield 
shift upon amidation at the gamma position, but not the alpha (Figure 2.3) In agreement 
with this hypothesis, both sets of methylene protons of 1c produced a slight shift in 
addition to no observable change in the lone stereocenter c at 4.5 ppm, thus conferring γ-
conjugation (Figure 2.4). 
 
2.1.1 Synthesis and Characterization of RTXγ-PgA by DCC/DMAP Coupling 
To further enhance the selectivity, 1a was subjected to additional steps to ensure 
complete γ-regioselectivity without enduring its total synthesis.18 Therefore, the 
regioselective opening of glutamic anhydride by PgA using stoichiometric amounts of 
DMAP was pursued (Figure 2.5).10 Coupling conditions were sought to completely 
dissolve 1a prior to its dilution into dichloromethane (DCM) followed by the drop-wise 
addition of DCC in order to slowly form the predicted 1a-anhydride. The 1a-anhydride 
reacts at -40 °C with PgA in the presence of DMAP under a jacket of argon. The 
resulting 2b and 2c isomers yielded a profound increase in selectivity shifting to 1:9 α/γ. 
The crude mixture of compounds 2a-d was quickly identified by HPLC-UV with an 
elution order of 2a (23.10 min), 2b (24.31 min), 2c (24.49 min), and 2d (25.67 min). All 
compounds were monitored at 341 nm (Figure 2.6) and characterized by LC/MS (data not 
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Figure 2.3 1H NMR spectra of 1a. Solvent: CD3OD; Concentration: 6.5 mg mL-1. 
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Figure 2.4 1H NMR spectra of 1c. Solvent: CD3OD; Concentration: 3.2 mg mL-1. 
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Figure 2.5 General synthetic scheme for the selective amidation via anhydride (1a’) of 
1a using DCC and DMAP coupling reagents. Under the polar-aprotic DMF the γ-
carboxylate was positioned for direct nucleophilic attack by PgA. Prospective 
regioselectivities were verified by HPLC-UV. (R = aminopterin-thiophene of 1a) 
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Figure 2.6 Reverse phase HPLC trace of RTX-PgA conjugates synthesized using 
DCC/DMAP. (x-axis in minutes)  
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shown). Given previous characterization (Figure 2.3, 2.4), no attempt was made to 
procure their NMR spectra. The concomitant production of the dual modified antifolate 
2d was still present. From a synthetic and biological propose, 2d is incompatible as it is 
devoted to quenching any potential single modification and it’s α-modification is 
pharmacologically inert toward TS. To remove any prospect of forming 2d, PgA 
equivalents were paired with 1a (Table 2.2). The synthetic scheme was scaled to 100 µM 
and confirmed the reproducibility of achieving enhanced γ-selectivity (1:9 α/γ).  
Moreover, compound 2d had completely receded with an accompanying increase in 1a. 
Given 3a (21.00 min) is the starting material, it was easily recovered and recycled for 
additional syntheses (Figure 2.7). Under DCC/DMAP coupling the ratio of the isomers 
3b (22.48 min) and 3c (22.71 min) was shifted from 1:1.3 to 1:9 α/γ by direct cooling to -
40 °C in the presence of DMAP and purified under preparatory HPLC to yield 100% 
purity 4b with 90% γ-character (Figure 2.7).  
 
2.1.2 Binding Fidelity of RTXγ-PgA  
 To determine if any of the pharmacokinetic or dynamic parameters of 1a had been 
altered, isothermal titration calorimetry was performed on 4b and compared to 1a (Figure 
2.8). Both compounds produced a sinusoidal path resulting from their exothermic 
interaction with the dUMP-hTS complex. The enzyme was previously analyzed against 
dUMP and trace contents of DMF to alleviate any signal from their dilution: no signal. 
overlap was detected. Compound 1a bound to the dUMP-hTS complex in a 1:2.4 ratio 
with a disassociation constant of 0.068 µM. Both parameters were expected as at
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Table 2.2 Resulting regioselectivity improved under the auspice of a polar aprotic 
system, which enabled the regioselective ring opening of the intermediate anhydride 
(1a’) to favor the gamma position.  
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Figure 2.7 (A) HPLC trace of the crude reaction products using equimolar amounts of 
starting material, 1a, and PgA. (B) HPLC trace of post purification of 3b and 3c, 
yielding high purity 4b at 90% γ-regioselectivity. (x-axis in minutes) 
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Figure 2.8 The top section within each panel is raw exothermic calorimetric output of 
each compound recorded over time. The lower section of each panel is the binding 
isotherm for each titrant. (A) Bottom panel: binding isotherm of 1a (300 µM) with 
dUMP (100 µM) and hTS (15 µM). (B) Bottom panel: binding isotherm of 4b (300 
µM) with dUMP (100 µM) and hTS (15 µM).  
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saturating conditions hTS can bind both monomers with exceptional fidelity.19 The Gibbs 
free energy (-9.8 Kcal), enthalpy (-7588 ± 142 cal mol-1), and entropic parameters (7.47 
cal mol-1/deg) reported optimal hydrophobic and hydrogen binding which are all strongly 
indicative of selective binding.  
However, the behavior of 4b deviated from 1a with the γ-propargylation of its 
carboxylate. The addition of the large sp-sp hybridized system may have disrupted 
hydrophobic stability of the terminal end of the conjugate, leading to an increase in the 
entropic threshold to -17.2 cal mol-1/deg. This, in turn, yielded a poor binding avidity of 
4b and increasing the disassociation constant from 0.068 µM to 3.8 µM. Although still 
within the binding capability of hTS (ΔG, -7.4 kcal; ΔH, -1.258X104 ± 1195 cal mol-1; N, 
1.6), the 4b dUMP-TS system was evaluated spectrophotometrically to evaluate its 
inhibitory capabilities. It was demonstrated that 4b still possessed inhibitory capabilities 
and functioned as a capable inhibitor (personal communication with Dr. Leslie Lovelace).  
 The 57-fold decrease in binding suggests that alteration of the gamma unit of 1a 
must take into account the enzyme's surface and active site environment. Based on the 
crystal structure of 1a with dUMP-TS, the selective placement of the gamma-carboxylate 
is seen to coordinate through water-networked hydrogen bonds.20 Although speculative 
without a crystal structure, it is likely that inserting the bulky electrophilic alkyne where 
the columbic coordination is perturbed is the contributing factor to the deterioration of 1a 
binding characteristics.   
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2.1.3 In situ CuAAC Reaction with RTXγ-PgA and Az42  
 Our effort to synthesize a potential biological probe resulted in the synthesis, 
characterization, and biophysical evaluation of compound 4b. To determine its in vitro 
efficacy, 4b was introduced to TS overexpressing cells (CHL-TS PJZ205/200) using a 
novel fluorogenic coumarin dye (5a, 3-azido-7-hydroxycoumarin) which lays dormant 
until it undergoes Cu(I)-catalyzed alkyne-azide cycloaddition (CuAAC) reaction with a 
reactive alkyne [21]. This bioorthogonal reaction is highly specific due to the selective 
reactivity between azides and alkynes, which are not endogenous elements in nature.22 
(Figure 2.9) 
 The confocal analysis of the CuAAC reaction was evaluated under various 
conditions in which the reagents, 4b, and 5a, were tested for background fluorescence 
(Figure can be see in Figure 2.10 and 2.11). Panel C showed a sharp increase in 
fluorescence indicating the CuAAC reaction had taken place. Within the overlay of panel 
C the propidium iodide nuclear stain clearly demarcates the perimeter of the nucleus and 
the presence of the click conjugate 6a is revealed by the pink hue generated from the blue 
and red overlap (Figure 2.10). This suggests the CuAAC reaction had taken place while 
4b was in a ternary complex with TS and dUMP. Of particular interest are panels F-G, 
where both 4b and 5a are incubated as separate components (Figure 2.11). 
 Neither panels produced any notable fluorescence in the DAPI channel where the 
6a conjugate is expected to actively fluoresce after the CuAAC reaction. Moreover, it 
was speculated that the combination of the azide-alkyne might possess a low order of 
propinquity and efficient ligand-alignment to undergo in situ CuAAC.23
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Figure 2.9 General scheme for the CuAAC reaction with Az42 (5a) and N3-APOP-FITC (5b) to yield 6a and 6b, respectively.  
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Figure 2.10 Confocal analyses of the CuAAC reaction with compound 4b and 5a in 
CHL-TS PJZ205/200 cells. Conditions: (A) no reagents or dyes. (B) 4b and CuSO4. (C) 
4b, TCEP, CuSO4, 5a. (D) TCEP, CuSO4. Panel C clearly indicates a strong presence 
of the CuCAA reaction in hTS overexpressing cells. All wells counter stained with 
propidium iodide for nuclear representation. Scale bars are 10 µm. 
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Figure 2.11 Confocal analyses of the CuAAC reaction with compound 4b and 5a in 
CHL-TS PJZ205/200 cells. (E) 4b, TCEP, CuSO4. (F) 4b. (G) 5a. (H) 4b and 5a. All 
wells counter stained with propidium iodide for nuclear representation. Scale bars are 
10 µm. 
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However, given the entropic parameters of 4b, the lack of fluorescence in panel H 
(Figure 2.11) confirms that both a reducing agent (TCEP or Sodium Acorbate) and Cu(I) 
are required to facilitate the 1,3-Hugsien cycloaddition, which forms the 1,2,3-triazole is 
responsible for the fluorogenic activation of 5a.24 
 To validate the previous findings, the experiments above were repeated in CHL-TS 
PJZ205/200 and CHL-TS Null cell lines in addition to the application of a TS-specific 
antibody (Ab+TS-647) for co-localization (Figure 2.12). Panel A shows the resultant 
fluorescence from the 6a product with overlap noted within the same regions as those 
stained with the TS-specific antibody (Figure 2.12). However, panel B, the negative 
control, shows some low levels of fluorescence from either 4b or 5a. In comparison with 
the TS stain of panel B, it can be seen that the background fluorescence does not correlate 
entirely with the signal produced by the TS Ab+TS-647.  Thus, it is unlikely that either 
component exhibits any characteristics of random fluorescence. Importantly, panels C 
and D confirm that fluorescence exhibited in panel A and, therefore, in panel C of figure 
2.6, is due to the presence of TS, as the 6a conjugate does not display non-specific 
binding or off-targeting capabilities. This is reaffirmed by the lack of signal in both 
Ab+TS-647 fluorescent micrographs. (Figure 2.12) 
 Due to the low background exhibited by 4b in figure 2.8 and the close proximity 
with which 5a must aligned with the active alkyne of 4b, an alternative longer 
wavelength dye with a extended linker was proposed. The N3-APOP-FITC (5b) linker-
dye was used to demonstrate the viability of an alternate probe and to alleviate the 
potential for false positive CuAAC between the blue emitting 5a and 4b. The linker 
possesses a terminal azide moiety for active CuAAC, which is tethered to two three-
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Figure 2.12 Fluorescent confocal micrographs of 6a in CHL TS overexpressing and 
null cell lines. (A) 6a CuAAC in TS overexpressing cells are clearly visible and 
detected with the +TS 647-conjugated Ab (third column). (B) CuAAC negative 
control (no catalysts) shows low background. (C, D) TS null cells show no signal of 
any 6a fluorescence or TS (third column). The overlay of C and D includes their 
respective DIC. All cells counter stained with propidium iodide (second column). 
Scale bar is 10 µm. Taken with 60× Apo Oil. 
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methylene spacers with an internal amide and the carboxy-terminus of the linker 
conjugated to FITC. In panels A-D a sharp increase in the fluorescence within the DAPI 
filter is seen to increase in a concentration dependent manner (Figure 2.13). Although the 
GFP channel records the presence of the 5b CuAAC reaction (no background within the 
inset for free dye), the same corresponding reaction shows activity in the DAPI filter.  
This phenomenon indicates that 4b might be fluorescent, but only in relationship 
to the levels external dye is administered and, therefore, is dependent on the CuAAC or 
triazole formation. This is because the addition of 4b was constant (25 µM) and free 5b 
(insets in all panels) did not produce any activity in either the DAPI or GFP filters. 
(Figure 2.13) Potentially, channel overlap, or bleed, appears to occur at the expense of the 
CuAAC reaction. However, it stands to be more reasonable to assume the triazole itself 
possesses fluorescent properties because, as the threshold of CuAAC rose in proportion 
to the amount of azide-dye added, there was an accompanying increase in signal within 
the DAPI channel. Provided with this posit, it was pertinent to further investigate the role 
of 4b and its potential cross-fluorescence.  
In order to investigate the fluorescent relationship between 4b and 5b, flow 
cytometry was used to measure their prospective interactions in CHL-TS pJZ205/200 cells 
(Figure 2.14). Here, 25 µM of 4b and 5b was applied to cells as the signal and spatial 
representation of the dye at this concentration was superior to those at the other three 
concentrations seen in figure 2.13. Plot A2 illustrates the CuAAC signal from both the 
488 (5b) and 405 (4b) channels, demonstrating that the reaction occurred as evidenced by 
the population in the second quadrant, Q2. Interestingly, both negative controls seen in 
plots A3 and A4 are free 5b and 4b, respectively, with Q3 of plot A3 occupying the most
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Figure 2.13 Fluorescence micrograph of the CuAAC reaction with 4b and the 
extended linker 5b. (A-D) Concentration of 5b varied for each CuAAC rxn 
demonstrating maximum signal strength and cellular visualization. Both the DAPI and 
GFP filters represent the CuAAC reaction between compound 4b and the dye-linker 
with negative controls for the latter (inset). Scale bar is 10 µm. Taken with 60× Apo 
Oil lens. 
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Figure 2.14 (A) Flow cytometry dot plots for compound 4b and 25 µM 5b dye in CHL-TS pJZ205/200 cells: (A1) Negative control. 
(A2) Representative CuAAC reaction. (A3) 25 µM 5b dye. (A4) 25 µM compound 4b. (B) Histogram flow analysis for compound 
4b (Alexa Fluor 405-A) in in CHL-TS pJZ205/200 cells demonstrates the fluorescence transmission of 4b (A4, B4) is significantly 
altered when compared the transmission generated for the CuAAC reaction (A2, B2). The designation for histograms B1-B4 
follows those of the dot plots for A1-A4. 
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signal and not for 4b. These controls show 4b is not a fluorescent product under the 405-
channel nor has the azide-dye undergone any type of CuAAC reaction. The relevance to 
whether 4b is fluorescent will only be apparent under conditions where (i) triazole 
formation occurs without an azide-fluorophore or (ii) triazole formation can only be 
detected at a narrow emission that precludes counter fluorescence from either 4b or 
azide-associated compounds.  
 Under CuAAC conditions, histogram A2 shows a distinct shift under the 405-
channel from the negative control, A2. This suggests that formation of the triazole, and 
not 4b itself, is responsible for generating a fluorescent signal. Additionally, histogram 
4B, the negative control for 4b, mirrors that of histogram A2, clearly supporting the non-
fluorescent nature of free 4b (Figure 2.14). Lastly, it’s unlikely that 4b could exhibit any 
proportional signal while bound in a ternary complex with dUMP-TS. The potential to 
reach any point of conjugation necessary for fluorescence can only be accessed by the 
triazole, as it is presumably solvent exposed, whereas the buried pterin ring system or the 
thiophene moiety are deep within the binding pocket of the 6bdUMPTS ternary 
complex.  
 
2.2 EXPERIMENTAL 
2.2.0 Synthesis and Characterization of RTXγ-PgA by EDCI/NHS Coupling 
Dr.’s Jiangli Fan, Yi Chen, and Honglin Li graciously performed the synthesis of 
4b for the use of all cell assays. The following is a brief analysis of their synthetic 4b for 
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the use of all cell assays. The following is a brief analysis of their synthetic protocol. In a 
500 mL round bottom flask, 2.1 mmol (1 g) of 1a was dissolved in 10 mL of DMF and 
cooled in a water-ice bath. To the reaction, 2.5 mmol (0.260 g) of NHS and 2.5 mmol 
(0.44 g) of EDCI were added. The resulting mixture was stirred will in the ice bath for 
0.5 hrs until a white precipitate formed. A solution of PgA (0.124 g, 2.25 mmol) in 5 mL 
of DMF was added. The resulting mixture was allowed to come to room temperature and 
stirred for 24 hrs. The reaction mixture was poured into water (100 mL) and stirred for 30 
min to form a precipitate. The crude product was purified over a RP C18 10.0 x 250mm, 
10 µm column at 6 mL min-1using a 25% ACN (0.05% TFA) to 90% gradient in 60 min. 
Peaks were detected at 220 nm and confirmed via ESI LC/MS. Fractions were collected, 
pooled, and dried under lyophilization to yield 4b as a brown-yellow solid; 1H NMR (400 
MHz, CD3OD) δ 1.98 (1H, m) 2.15 (1H, m), 2.31 (1H, m), 2.41 (1H, m), 2.52 (3H, s), 2.5 
(1H, d, J = 9.2 Hz), 3.12 (1H, s), 3.89 (1H, s), 3.95 (1H, s), 4.7 (1H, s), 6.0 (1H, d, J = 4.4 
Hz), 7.6 (1H, d, J = 8.4 Hz), 7.7 (1H, d, J = 8.2 Hz), 8.1 (1H, s); Compound 1a purchased 
from Sequoia Research Ltd.; 1H NMR (400 MHz, CD3OD) δ 2.0 (1H, m), 2.2 (1H, m), 
2.0 (1H, m), 2.4 2.0 (1H, m), 3.1 (3H, s), 4.5 (1H, m), 4.66 (2H, s), 5.97 (1H, d), 7.49 
(1H, s), 7.5 (1H, d, J = 9.5 Hz), 7.7 (1H, d, J = 8.1 Hz), 8.06 (1H, s). 
 
2.2.1 Synthesis and Characterization of RTXγ-PgA by DCC/DMAP Coupling 
To a 100 mL round-bottom flask were added 1a (47 mg, 103 µmol) in 2 mL of 
DMF under argon and cooled to 4 °C followed by the drop-wise addition of 6 mL of 
DCM with DCC (20 mg, 97 µmol) over 60 min. The flask brought to -40 °C in a dry ice-
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acetonitrile bath and where DMAP (12 mg, 99 µmol) in DCM was added via the septum. 
To the flask, the primary amine PgA (6.4 µL, 100 µmol) was added and reaction was run 
for 3 hours at -40 °C then allowed to reach to room temperature over night. The reaction 
was extracted 2× in 15 mL of water with DCM and pooled using a 250 mL separation 
funnel. The pooled water was evaporated under reduced pressure at 52 °C with ACN 
until dry. All samples were prepared for analytical and preparatory HPLC-UV using the 
corresponding methods. Analytical: Inject 20 µL over a RP C18 4.6 × 250 mm, 5 µm 
column from 10-80% ACN with 0.1% TFA at 1 mL min-1 in 45 min, monitoring peaks at 
269 and 341 nm.  For preparatory purification inject 94 µL over a RP C18 10.0 × 250-
mm, 5 µm column from 10-80% ACN with 0.1% TFA at 4.7 mL min-1 monitoring peaks 
at 269 and 341 nm. Peaks were identified and collect using MassLynx FractionLynx 
software.  
 
2.2.2 Enzyme Purification  
 Thymidylate synthase was partially purified according to the protocol previously 
reported.19  
 
2.2.3 Isothermal titration calorimetry 
 Isothermal titration calorimetry (ITC) was performed on a VPITC instrument 
(Microcal Corp.) with a 250 µL syringe. All ITC measurements were carried out at in 
degassed solutions at 26 °C. Approximately 52, 5 µL injections were made with 6-second 
 70 
duration and 120 seconds spacing. The macromolecule (TS) concentration was 15 µM in 
50 mM Tris-HCl, pH 7.4 with 1 mM EDTA and 20 µM BME, which is referred to as 
“Buffer A.” Titration was carried out in buffer A with the following reagents: 100 µM 
dUMP and 300 µM of either 1a or 4b. The data was processed using the manufacturers 
software ORIGIN.   
 
2.2.4 Cell Prep 
All cells were provided by Dr. Franklin G. Berger (University of South Carolina, 
Department of Biological Sciences). All cells were grown in a T75 flask under 10% fetal 
bovine serum (FBS) in high glucose Dulbecco's Modified Eagle's medium (DMEM) with 
100 U of penicillin-streptomycin (Pen-Strep) at 37 °C and humidified at 5% CO2. Cell 
line RJK33.13, a TS-deficient derivative of V79 Chinese hamster lung cells (CHL-TS 
pJZ205, CHL-TS pJZ205/200, CHL-TS Null) were grown to confluency and passaged at 
either 1:10 or 1:20 with 0.25% trypsin. CHL-TS Null cells were supplemented with 10 µM 
thymidine.  
 
2.2.5 CuAAC Assay and Image Analysis with Lab-TEKII Prep 
CHL-TS pJZ205/200 cells were seeded at 1×105 cell/well into a Lab-TEKII 8-
well chamber (Nalgene) that was coated with 10 µg/mL of fibronectin at 4 °C for 24 
hours. Cells were incubated for 6 hrs at 37 °C and then prepped for 30 min incubation 
with reagents according column A in table 2.3. Immediately after incubations wells were
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Table 2.3 CuAAC conditions for confocal analyses with compound 4b and 5a in CHL-
TS PJZ205/200 cells.   
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aspirated, washed 2× with phosphate buffered saline (PBS) and fixed with 250 µL of 
3.7% paraformaldehyde (pfa) for 10 min at room temperature. After fixation, cells were 
washed 2× with PBS and counterstained with propidium iodide (PI) at 2 µL/mL. Cells 
were washed 3× with PBS and dye-labeled by sequentially adding reagents according to 
columns B→E in table 2.3.  
The slide was wrapped in aluminum foil and incubated at room temperature (RT) 
for 60 min. The cells were aspirated and wash 3× in PBS. Approximately 10 µL of the 
antioxidant 1,4-diazabicyclo[2.2.2]octane (DABCO) was added per well and the chamber 
was released and covered with a 22x50 mm glass coverslip and sealed with nail polish. 
All data was collected on an Olympus IX81 confocal fluorescent microscope with either 
a 10× air objective or 60× apo oil lens.  
 
2.2.6 CuAAC Assay and Image Analysis with 12-well Prep 
Glass coverslips were added to a twelve-well plate and washed in ethanol 
followed by 3× washes with PBS. Each well was seeded with 1×105 cells and incubated 
overnight. All wells were prepped for 30 min incubation with 5a or 5b according column 
A in table 2.4 and 2.5, respectively. Immediately after incubations wells were aspirated, 
washed 3x with PBS and fixed with 250 µL of 3.7% pfa for 10 min at (RT). After 
fixation, cells were washed 2× with PBS and counterstained with PI at 2 µL/mL. Cells 
were washed 3× with PBS and dye-labeled by sequentially adding reagents (B→D) 
according tables 2.4 or 2.5. The trays were wrapped in aluminum foil and incubated at
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Table 2.4 CuAAC conditions for confocal analyses with compound 4b and 5b in CHL-
TS PJZ205/200 and CHL-TS Null cells.   
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Table 2.5 CuAAC conditions for confocal analyses with compound 4b and 5b in CHL-
TS PJZ205/200 cells to determine relationship between concentration of 5b and image 
resolution.   
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RT for 15 hrs. The cells were aspirated and wash 3× in PBS. Individual cover slips were 
removed and dried and set with 10 µL of DABCO or 15 µL of VectaShield and sealed 
with nail polish. All data was collected on an Olympus IX81 confocal fluorescent 
microscope with either a 10× air objective or 60× apo oil lens. 
 
2.2.7 Immunohistochemistry with 12-well Prep 
 Immediately after fixation, cells were washed 3× in PBS at 37 °C and 
permeabilized with 0.1% Triton X100 for 5 min. Cells were washed 3× in PBS and 
blocked in 10% goat serum with 50 mg mL-1 sucrose and 20 mg mL-1 bovine serum 
albumin (BSA, Rockcreek) in PBS for 90 min at RT. Cells were washed 3Χ in PBS and 
probed for 60 minutes with hTS primary antibody T-106 [1:40] in 5% goat serum with 
1% BSA in PBS.  
Cells were washed 3×, 5 minutes each in PBS followed by secondary probe Cy5-
ab-642 goat anti-mouse at 1:2000 in the same solution as the primary probe. Cells were 
washed 3 ×, 5 minutes each in PBS and counter stained with PI at 2 µL mL-1. Cells were 
washed with 3× with PBS and prepared for CuAAC reaction according to table 2.4 AND 
2.5. The trays were wrapped in aluminum foil and incubated at RT for 15 hrs. The cells 
were aspirated and wash 3× in PBS.  
Individual cover slips were removed and dried and set with 10 µL of DABCO or 
15 µL of VectaShield and sealed with nail polish. All data was collected on an Olympus 
IX81 confocal fluorescent microscope with either a 10× air objective or 60× apo oil lens. 
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2.2.8 Flow cytometry Cell Prep for CuAAC Reaction 
Cells were prepped as previously described in section 2.3.4. Cells were seeded in 
a 12-well plate at 1×105 cells per well and incubated at 37 °C at 5% CO2 for 24 hours. 
Cells were inoculated with 25 µM 4b in six wells filled with 1 mL DMEM and incubated 
for 60 min. Cells were washed with 1 mL, 1× in 37°C PBS and then lifted with 150 µL of 
0.25% trypsin for 3 min at 37 °C. Cells were centrifuged at 100 RCF for 3 min, aspirated 
and washed with 1% BSA in PBS at 37 °C. Additional centrifugation followed at 200 
RCF for three min where the cells were then aspirated and fixed in 100 mL of 3.7% pfa at 
37 °C for 15 min at RT. Cells were washed again with 1% BSA in PBS and pelleted at 
200 RCF for 3 min followed by permeabilization with 100 µL of Triton X-100 for 15 
min. Cells were washed again with 1% BSA in PBS and pelleted at 200 RCF for 3 min 
then prepped for CuAAC reaction.  
 
2.2.9 Flow cytometry of CuAAC Reaction 
To each positive control 100 µL of 1 mM CuSO4 and 250 µL of 2 mM histidine 
were pooled together and added to each well.  All wells were then diluted with 240 µL of 
PBS followed by 10 µL of 2.5 mM 5b. The CuAAC reaction proceeded upon the addition 
of 400 µL of 1 mM sodium ascorbate. The reaction was incubated for 30 min at RT with 
no light. Post CuAAC, the samples were washed with 1% BSA in PBS and pelleted at 
200 RCF for 3 min. The samples were aspirated and resuspended in 400 µL of PBS and 
analyzed immediately. 
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CHAPTER 3 
ANTIFOLATE-PROTAC INDUCED DEGRADATION OF THYMIDYLATE SYNTHASE  
 
3.0 INTRODUCTION 
 The importance of protein-protein interactions in regards to the etiology of 
disease cannot be understated. The ability to mitigate or disrupt these interactions relies 
heavily on the pharmacology of biopharmaceuticals or peptide conjugates.1, 2 Although 
examples of efficient small molecule targeted therapies have been shown, the ability to 
successfully influence these interaction remains difficult given the immense diversity 
protein substrates display on their surface or active site.3-5 Contrary to more classically 
targeted systems such as enzymes and transmembrane receptors, protein-protein actions 
are not dependent on small pharmacophore interactions. Rather, they undergo reciprocal 
interactions that are mediated through spatial recognition of surface exposed non-
contiguous amino acids.  
 A bifunctional molecule that recruits rather than disrupts protein-protein 
interaction has potential, should the substrate and the recruiting machinery coalesce to 
yield a therapeutic response.6 Such systems have shown great utility in cell free systems, 
fusion constructs, and drug-peptide/carbohydrate conjugates.7 Specifically the drug-
peptide chimera holds great appeal due to its bioorthogonal capacity and its reliance upon 
the endogenous machinery inherent to many cell types, but without any genetic assault.
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This system, qualified as the Proteolysis Targeting Chimera System (PROTACs) asserts 
targeted degradation via chemical control over the translational conscripts to which it 
targets.8 
At one pole of the chimeric compound is a substrate-specific ligand, designed to 
actively recruit a protein of interest (POI). Tethered by a chemical linker to the opposite 
pole of the chimera is a peptide signal-sequence designed to enlist an ubiquitin-protein 
E3-ligase, thus targeting the POI for ubiquitin-dependent proteasomal-degradation.9 The 
serviceable nature of the ligase is compounded, given there are over 600 E3-ligases of 
which the Skp1-Cullin-F-box (SCF) and von Hippel-Landau (VHL) are more widely 
studied.10-12 These systems have asserted direct in vitro protein degradation of steroid 
hormone receptors, aminopeptidases, aryl hydrocarbon-receptors, and hypoxia-molecular 
switches.8, 10, 13, 14  
 The VHL E3 ligase holds promising potential in anti-cancer therapy due to its 
transcriptional relationship with intracellular hypoxia, a condition known to up-regulate 
pro-angiogenic genes.15 The VHL tumor suppressor complex is comprised of elongins B 
and C, along with Cullin1 and ring box protein 1 (Rbx1).16 Under normoxic conditions 
the complex constitutively ubiquinates hypoxia inducible factor 1α (HIF1α) by 
recognition of an internal hydroxylated proline located in a conserved 7-amino acid 
sequence.17, 18  
Interestingly, coupling the HIV-tat translocation peptide to the HIF1α 
oxygen-dependent degradation domain (ODD) facilitates cellular entry with an 
accompanying angiogenic response along with induction of glucose transporter-1 gene 
expression.19 This suggests that using the prolyl hydroxylation site in foreign 
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polypeptides can both serve as a VHL-E3 ligase substrate, and prevent HIFα from up-
regulating its targeted genes. A candidate substrate for the PROTACs system is de novo 
source of the thymidine monophosphate (TMP): human thymidylate synthase (hTS, from 
this point on it will be referred to as TS unless otherwise noted).  
As an overexpressed substrate in cancer, its potential applicability for PROTAC 
intervention is significant due to the following attributes: (i) TS represents a metabolic 
“bottleneck” for the pyrimidine TMP, thus presenting a pharmacological opportunity to 
induce cell death, (ii) TS possesses a large accessible array of modifiable quinazoline-
based TS-directed antifolates. These antifolates can serve as the foundation for the TS-
directed portion of the heterobifunctional PROTAC conjugate, and (iii) its [TS] 
intracellular stability is regulated by an internal bipartite degron and not direct 
ubiquitination.20 
Selective chemical remodeling has already been demonstrated in potential TS 
targeted antimetabolites though elongation of the [antifolate] methylene bridge or through 
cyclopenta[γ]quinazoline diglutamyl arrangements at the carboxy-terminus.21, 22 Of 
particular interest is the antifolate raltitrexed (RTX, Tomudex) and its nanomolar affinity 
toward TS. Previous attempts to modify RTX and its analogs with glutamic acid 
substrates successfully demonstrated the facile synthesis of gamma-modification to the 
terminal glutamic residue.23-25 Here we describe our approach to the synthetic 
construction and in vitro potential of a gamma-linked TS-degradation directed RTX-
PROTAC system using the VHL-E3 ligase directed HIF1α signal peptide (Figure 3.1). 
By affixing the HIF1α signal to the C-terminal carboxylate of RTX, the Ub-machinery is 
postulated to recognize the prolyl hydroxylated-peptide, induce TS-ubiquination and its
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Figure 3.1 A general diagram illustrating the theoretical recognition of TS by the 
PROTAC HIFα hydroxyproyl moiety fused to TS bound-raltitrexed. Conferring 
substrate identity, the formation of the VHL-TS complex is accomplished with 
subsequent polyubiquination via the E2-congating subunit.  
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subsequent proteasomal degradation. This approach would prevent TS from escaping Ub-
independent degradation, thus asserting intracellular control over the endogenous 
mechanism(s) that stabilize TS and promote cell death. 
 
3.1 RESULTS AND DISCUSSION  
3.1.1 Synthesis of a TS-targeted PROTAC 
  Using the ALAPYIP peptide for E3-ligase recognition has been shown to serve 
as the minimum identification sequence for the VHL tumor suppressor protein.18 Under 
hypoxic conditions HIF1α is not a VHL substrate and is therefore not post transnationally 
modified at P564.26 Given that cancer cell lines function under hypoxic environments it 
was decided to omit the internal proline residue within the 8-mer-recognition [ALAPYIP] 
domain and synthesize the peptide with the VHL recognition residue, hydroxyproline 
(O). By circumventing the dependence of the intracellular hydroxylation of the 
HIF1α peptide we sought to remove any possibilities of generating an inert VHL 
substrate that would fail to result in (poly)ubiquitination. For the design of the TS-
targeted PROTAC-1 we decided to rely upon the simple scaffolding features that solid 
phase peptide synthesis (SPPS) affords (Figure 3.2).27  
A glycine trimer was coupled the C-terminus of 2 to generate 3a in order to 
confer an unobtrusive linker and produce a stable chemical handle. Based on the crystal 
structure of a hyrodxylated HIFα bound to the VCB (VHL, elongin C, and B) complex, 
we hypothesized that the peptides structural arcing engendered by both the proline and 
hydroxyproline residues should be complimented with a ridged handle that orthogonally 
extends from the C-terminus away from the VCB complex (Figure 3.3).18 The 
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Figure 3.2 General schemes for the synthesis of both PROTAC-1 and PROTAC-2. 
Anatomies of both conjugates are shown with the gamma-carobxylate of raltitrexed 
tethered to a linker (blue), which presents the HIFα peptide (green) for VHL-E3 
recognition.   
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Figure 3.3 (a) Crystal structure of the VCB-COOD complex. The pVHL (blue) 
complexed to both elonging B (red) and elonging C (orange) with accompanying 
hydroxylated HIFα  or carboxy-terminal oxygen-dependent degradation motif 
(COOD). Site 1 possesses the primary binding site where the hydroxyl modification to 
P564 binds to the pVHL’s Hyp-binding pocket through an extensive hydrogen-
bonding network mediated by water; whereas site 2 only interacts with one residue 
negating any sequence specificity and thus is omitted from the PROTAC sequence.  
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chemical synthesis of 4a was completed upon ligation of raltitrexed to the C-terminus of 
3a. It’s important to note, that no regioselectivity was conferred through the HOBt/HBTU 
coupling and thus both regioisomers are present. HPLC purification yielded 4a 
(PROTAC-1) with a 78% recovery from 1 in 76% purity. Control peptides 2 and 3a were 
synthesized in parallel to serve as in vitro controls (Figure 3.2). It was reasoned that 
triglycine-bridge may attract proteolytic digestion or may confer excessive structural 
rigidity that would prevent substrate identification, thus an alternative to the linker in 3a 
was examined. Substituting for the triglycine linker, a flexible protease-resistant two-
residue polyethylene glycol-FMOC (PEG) chain was coupled to 2 to give 3b followed by 
direct coupling to RTX (4b, PROTAC-2).   
 
3.1.2 PROTAC-1 in vitro Challenge 
 To demonstrate the inhibitory effects of PROTAC-1 we monitored TS expressing 
CHL-TS pJZ205 and overexpressing CHL-TS pJZ205/200 cell lines over a 4-day time 
course. PROTAC-1 had a moderate inhibitory effect, when compared to free RTX (IC50 
0.002 µM), on CHL-TS pJZ205 cells, producing an IC50 of 0.20 µM (Figure 3.4). The TS-
overexpressing cell line showed no effect upon administration of PROTAC-1, confirming 
the overabundance of TS had muted any growth inhibition or potential degradation.  
To substantiate that growth inhibition was due to the presence of the PROTAC-1, 
both growth assays were repeated with a thymidine rescue added. It’s reasoned that 
supplying the cell with free thymidine can reverse any deleterious pharmacological action 
upon TS, thus preventing a thymineless death. Under the auspice of a thymidine rescue, 
both cell lines remained resistant to the pharmacological effect of PROTAC-1,
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Figure 3.4 The IC50 performance of PROTAC-1 in CHL-TS pJZ205 (red) and 
pJZ205/200 TS overexpressing cell lines (dark green) with concomitant thymidine 
rescues (blue and light green, respectively) as compared to free raltitrexed (light blue, 
IC50 = 0.002 µM). 
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confirming the inhibition is the result of the interaction between TS and PROTAC-1 
(Figure 3.4). Although the rescue corroborated PROTAC-1’s actions upon TS, it was still 
unknown if the effects were mediated through ubiquitin-depended proteasomal 
degradation or alternate mechanisms of cell death.31 
 
3.1.3 PROTAC-1 Ubiquitin Analysis  
To determine the extent of PROTAC-1’s relationship with the VHL ligase, and 
thus the Ubiquitin Proteasomal System (UPS), TS expressing CHL-TS pJZ205 cells were 
exposed to 1x and 10x the IC50 of PROTAC-1 in the presence of the proteasomal 
inhibitor, MG132 (Figure 3.5). In an effort to qualitatively assess the potential 
degradation of TS, RTX was used to act as a control due to its inherent ability to stabilize 
the TS complex (RTXdUMPTS), thus increasing TS intracellular concentration. 
Hence, cells were similarly exposed to 1× and 10× the IC50 of RTX (0.002 µM). 
Diminishing signal from TS was not observed in the western analysis under either 
concentration analyzed for PROTAC-1 (Figure 3.5A). Rather, each PROTAC-1 TS band 
closely paired with its RTX cognate both with and without M132 exposure.  
Given the potential stabilizing effect of RTX, we next took measures to 
investigate whether the inhibitor effect of PROTAC-1 was attenuated due to poor VHL 
recognition and the UPS machinery was only capable of moderate signal suppression. 
The lysates were analyzed again under the preceding conditions, but probed for signals of 
UPS directed degradation of TS (Figure 3.5B). Under conditions free from MG132, no 
signal of TS degradation was apparent. Methods to extend the exposure time of the film 
failed to yield any qualitative evidence of PROTAC-1 facilitating the ubiquitination of
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Figure 3.5 Western blot analyses of 1× and 10× PROTAC-1 cell lysates from CHL-TS 
PJZ205 cells under MG132 inhibitor. (A) Only non-specific bands above TS (RTX-
dUMP-TS) were noted with no indication of ubiquitin-promoted proteolysis in the 
presence of the proteasomal inhibitor MG132. (B) Lysates were analyzed again, but 
with ubiquitin specific antibody. No evidence of TS ubiquitination was realized.  
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TS. Because each signal in the western analysis closely resembled the stabilizing features 
of RTX, we sought to determine if RTX had been excised and was therefore free to bind 
TS. Intracellular stability of PROTAC-1 conjugates 2 and 3a were analyzed in CHL-TS 
pJZ205 cells to determine their potential effect upon TS inhibition (Figure 3.6). While 
PROTAC-1 reproduced its IC50 potential, no effects were observed for either conjugate 2 
or 3a, suggesting that the stabilization effect is due to RTX bound to TS. However, no 
evidence in the literature could be located regarding the expression levels of the VHL 
ligase in CHL-TS pJZ205 cell lines. To alleviate these concerns, an identical Western blot 
analysis was repeated in the human colon cancer cell line HCT116. As with the first 
experiment in figure 3.5A, no discernable evidence of TS degradation was present 
(Figure 3.7).  
Finally, we questioned whether PROTAC-1 was acting in accord of the 
pharmacokinetic action of RTX or inducing attenuated levels of degradation in an 
ubiquitin independent manner. To evaluate this concern, we measured the half-life of 
both RTX and PROTAC-1 over a 24 hr period in HCT116 cells. The dosimetry analysis 
for the half-life analyses concluded that PROTAC-1 exhibits a stabilizing effect up on 
TS, rendering the conjugate a less potent form of its free-from drug.  
To this end, we explored the possibility that the tri-glycine linker was too rigid 
and performed a subsequent times course study on PROTAC-2 (Figure 3.8). Curiously, 
PROTAC-2 produced a 500-fold increase (> 100 µM IC50) in stabilization in both CHL-TS 
pJZ205 and overexpressing CHL-TS pJZ205/200 cell lines compared to its counterpart, 
PROTAC-1 (IC50 = 0.20 µM). These results indicated that PROTAC-2 is ineffective due 
to the PEG linker. It’s likely that its inherent flexibility and restricted atomic length
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Figure 3.6 Representative plot for the IC50 of the HIFα peptide (red), HIFα with 
glycine linker (blue), and PROTAC-1 (green) versus free raltitrexed (pink, IC50 = 
0.002 µM in HCT-116 cells. The lack of inhibitory potential of either the HIFα or 
HIFα-GGG peptide demonstrates the necessity of RTX in order to target TS and 
induce growth inhibition.  
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Figure 3.7 Western blot analyses of 1× and 20× PROTAC-1 IC50 concentration in 
HCT116 cells under MG132 inhibitor. No evidence of PROTAC-1 induced 
degradation of TS is apparent. All bands report RTX stabilized TS complexes.  
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Figure 3.8 Half-life analysis of PROTAC-1 in HCT116 during 24-hour exposure to 
cyclohexamide. (A) Western blot analysis of control cells (red) yielded within the 
range of wtTS half-life (9.6 hrs) while PROTAC-1 (blue) mirrored the stabilizing 
effect of free raltitrexed (green). (B) Graphical representation of Western blot 
demonstrating the stabilization effect of PROTAC-1.  
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disrupts the conformational entropy required for proper ligand-active site docking. 
Provided that others have been unable to show TS in an ubiquitinated state, the assertion 
that TS follows an ubiquitin-independent proteasomal degradation pathway, stands.32 
 
3.2 EXPERIMENTAL  
3.2.1 General Procedure for Solid Phase Peptide Synthesis of PROTAC-1 
To a 20 mL reactor cartridge was added Wang-Gly-Fmoc resin (330 mg, 0.20 
mmol) followed by solvation in DMF. A fresh solution of 20% piperidine in DMF was  
added to the reactor and agitated for 30 min. The resin was then filtered and washed with 
DMF (3 × 5 mL) and filtered again. The following is the general procedure for each 
Fmoc-amino acid coupling: The resin was washed (3 × 5 mL) in DMF and filtered. To 
separate 50 mL flask was added Fmoc-amino acid (4 eq, 2.4 mmol), HBTU (2.9 eq, 1.74 
mmol), NMM (4 eq, 2.4 mmol).  
The reagents were dissolved in 10 mL of DMF, transferred tot he reaction 
cartridge and agitated for 45 min. A Kaiser test was administered to determine reaction 
completion.29 The resin was washed (3 × 5 mL) in DMF and filtered. The resin was 
deprotected in 20% piperidine in DMF and agitated for 45 min after which a second 
Kaiser test was performed. The residues were added in the following order: Fmoc-Proline 
(×2), Fmoc-Isolucine, Fmoc-Tyrosine, Fmoc-Hydroxyproline (×2), Fmoc-Alanine, 
Fmoc-Leucine, Fmoc-Alanine for 2, Fmoc-Glycine (3×) for 3a.  
For the synthesis of 4a in 10 mL flask raltitrexed (2 eq, 0.215 mmol), HBTU (2.9 
eq, 1.74 mmol), NMM (4 eq, 2.4 mmol) was dissolved in 7 mL of DMF. Reagents were 
transferred to each reaction cartridge with resin-bound deprotected 3a and 3b and 
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agitated for 60 min. The resin was washed (3 × 5 mL) in DMF, (3 × 5 mL) DCM, and (3 
× 5 mL) in MeOH, filtered, and dried. Peptides 2, 3a, and 4a were liberated from the 
resin under 9 mL of 95% TFA in H2O for 2 hrs. The resins were drained and the eluent 
was collected. The resins were washed again in 9 mL of 95% TFA and pooled. Each was 
subsequently dried under N2 until a yellow or white film appeared. To each was added 
ice-cold diethyl ether to form a precipitate. The precipitate was centrifuged at 9,000 
RPMs at 4° C for 15 min. The clear eluent was decanted the remaining material was 
lyophilized overnight to yield the crude forms of 2 (26.3 mg, 35.3 µmol) 3a, (41.7 mg, 
42.2 µmol), 4a (26.5 mg, 18.5 µmol).  
All crude peptides were identified and purified by HPLC using a 250 × 10-mm, 5 
µm RP C18 column at 5 mL min-1 from 10-65% ACN in 0.1% TFA for 65 min. Injections 
of 1.2 mL were monitored at 215, 276, and 304 nm. Fractions were pooled, concentrated, 
and lyophilized. Purified products were characterized using ESI LCMS over 150 × 2.0-
mm, 3 µm RPC18 over 10-65% ACN (0.1% formic acid) gradient in 45 min. Products 2, 
3a, and 4 were identified at [M+H]+ 818, [M+H]+ 988.7, and [M+H]+ 1428.5, 
respectively.  
 
3.2.2 General Procedure for Solid Phase Peptide Synthesis of PROTAC-2 
To a 20 mL reactor cartridge was added Wang-Gly-Fmoc resin (166 mg, 0.10 
mmol) followed by solvation in DMF. A fresh solution of 20% piperidine in DMF was 
added to the reactor and agitated for 30 min. The resin was then filtered and washed with 
DMF (3 × 5 mL) and filtered again. The following is the general procedure for each 
Fmoc-amino acid coupling: The resin was washed (3 × 5 mL) in DMF and filtered. To 
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separate 50 mL flask was added Fmoc-amino acid (2.9 eq, 0.29 mmol), HBTU (2.9 eq, 
0.29 mmol), NMM (4 eq, 0.4 mmol). The reagents were dissolved in 10 mL of DMF, 
transferred tot he reaction cartridge and agitated for 45 min. A Kaiser test was 
administered to determine reaction completion.29 The resin was washed (3 × 5 mL) in 
DMF and filtered. The resin was deprotected in 20% piperidine in DMF and agitated for 
45 min after which a second Kaiser test was performed. The residues were added in the 
following order: Fmoc-Proline (×2), Fmoc-Isolucine, Fmoc-Tyrosine, Fmoc-
Hydroxyproline (×2), Fmoc-Alanine, Fmoc-Leucine, Fmoc-Alanine for, Fmoc-AEEA 
(×2) for 3b. The resin was deprotected in 20% piperidine in DMF and agitated for 45 min 
after which it was washed in DMF (3 × 5 mL), DCM (3 × 5 mL) and stored at 4 °C.  
For the synthesis of 4b in 10 mL flask RTX (46.5 mg, 0.101 mmol) was dissolved 
in 5 mL of DMF. To 45 mL of DCM in a 250 mL round bottom flask the 5 mL solution 
of RTX was added and jacketed over argon. The reaction mixture was cooled on ice for 
10 minutes and bubbled with nitrogen. In 6 mL of DCM, DCC (21.1 mg, 0.102 mmol) 
was dissolved and added drop wise to the reaction over 30 min. The reaction incubated 
for 80 min at 4-10 °C under argon and then was brought to -40 °C on dry ice and 
acetonitrile. In 2 mL of DCM, DMAP (12.3 mg, 0.100 mmol) was dissolved and added to 
the reaction in four 500 µL aliquots. The resin bound 3b was added in 3 mL of DCM and 
maintained at -40 °C for three hours and then allowed to reach room temp over night.  
Resin bound 4b was transferred to a reaction cartridge and washed in DCM (3 × 5 
mL), filtered, and dried. Peptide conjugate 4b were liberated from the resin under 10 mL 
of TFA for 2 hrs. The resin was drained and the eluent was collected. The resin was 
washed again in 10 mL of TFA and pooled and dried under N2 until a yellow film 
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appeared. To the flask was added ice-cold diethyl ether to form a precipitate. The 
precipitate was centrifuged at 9,000 RPMs at 4 °C for 10 min. The clear eluent was 
decanted the remaining material was lyophilized overnight to yield the crude forms of 4b 
(8.9 mg, 6.3 µmol). The 4b crude was identified purified by HPLC using a 250 × 10-mm, 
5 µm RP C18 column at 5 mL min-1 from 10-65% ACN in 0.1% TFA for 65 min. 
Injections of 1.2 mL were monitored at 269 and 341 nm. Fractions were pooled, 
concentrated, and lyophilized. Purified products were characterized using ESI LCMS 
over 150 × 2.0-mm, 3µM RPC18 over 10-65% ACN (0.1% formic acid) gradient in 45 
min. Purified product 4b (7.7 mg, 86.5%) was identified at [M+H]+ 1402.7 m/z. 
 
3.2.3 General Cell Preparation 
All cells were provided by Dr. Franklin G. Berger (University of South Carolina, 
Department of Biological Sciences). All cells were grown in a T75 flask under 10% fetal 
bovine serum (FBS) in high glucose Dulbecco's Modified Eagle's medium (DMEM) with 
100 U of penicillin-streptomycin (Pen-Strep) at 37 °C and humidified at 5% CO2. Cell 
line RJK33.13, a TS-deficient derivative of V79 chinese hamster lung cells (CHL-TS 
pJZ205, CHL-TS pJZ205/200) were grown to confluency and passaged at either 1:10 or 
1:20 with 0.25% trypsin.33 
 
3.2.4 Growth Inhibition Studies for PROTAC-1 and PROTAC-2 
To determine the growth inhibition response of compounds 2, 3a, 4a, and 4b, 
500,000 cells/well of CHL-TS pJZ205 and CHL-TS pJZ205/200 were each plated in four 6 
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well plates and allowed to adhere over 4 hours before drug treatment with ranging 
concentrations of each compound were added in duplicate fashion. After five days, the 
number of surviving cells was counted with a hemocytometer after counter staining with 
Tyrpan Blue and the IC50 determined. The inhibition of the PROTAC conjugates was 
generously performed by Karen Barbour (University of South Carolina, Department of 
Biological Sciences). 
 
3.2.5 Ubiqutination Analysis for PROTAC-1 in CHL-TS pJZ205 and HCT116 Cells 
Cells were plated in 100 mm dishes with 2×106 cells per plate. Cells analyzed for 
ubiquitinated products were pretreated with 25 mM MG132 4 hours before RTX and 
PROTAC-1 inoculation. Cells were then inoculated with 0.002 and 0.02 µM RTX with 
0.2 and 2.0 µM of 4a, to plates both with and without MG132, respectively. Cells were 
harvested with a rubber policeman and lysed with M-PER (ThermoFisher) and treated 
with 5 mM PMSF, 200 µg mL-1, aprotinin, 100 µg mL-1 pepstatin, and 50 µg mL-1 
leupeptin according to manufactures instructions. Crude lysates were centrifuged at 
13,000 RPM for 15 min at 4 °C. The extracts were quantified using the Bio-Rad assay 
reagent with BSA standard.  
Western analysis was performed under standard techniques. The blot was probed 
for TS and ubiquitin using a monoclonal antibodies provided by Dr. Franklin G. Berger 
(University of Southern Carolina, Department of Biological Sciences). Equal loading of 
the lysates was monitored by re-probing the nitrocellulose blots with an anti-actin 
monoclonal antibody (Sigma-Aldrich, Clone AC-40). For detection of TS the blots were 
visualized using the appropriate species dependent HRP-antibody with the ECL 
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chemiluminescence kit from Amersham Biosciences. All blots were run with exposure 
controls to correct for film exposure and normalized to actin via densiometric analysis 
using ImageJ software.  
 
3.2.6 TS Half-Life Studies for PROTAC-1 
The half-life of TS in HCT116 cells under exposure to 2 µM of 4b and 0.2 µM 
RTX was assessed according to the protocol previously reported.32  
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CHAPTER 4 
COMBINATORIAL DEVELOPMENT OF HYDROPHOBIC-TAGGED RALTIREXED 
 
4.0 INTRODUCTION 
 The traditional routes of probing or modulating protein function have directed 
their scope toward alterations at the transcriptional level to engineer or solicit a desired 
phenotype. Within this subtext are chemical modifiers that induce or suppress gene 
expression either at the level of transcription, translation, or through post-translational 
control. These levels of control afford a strict regulation over the dynamic processes that 
modulate the invoked protein phenotype. Through RNAi mediated tools, the conditional 
knockdown of specific protein phenotypes has emerged as popular and highly desirable 
approach for manipulating post-translational events and their resultant gene products. 
However, RNAi still cannot afford the spatial-temporal control necessary to achieve a 
post-translational effect capable of delivering a sustained degradation response. Thus, to 
meet this precise and defined metric, many small molecules have been tailored to 
selectively delineate protein function in order to exert a degradation effect, as opposed to 
inhibitory, upon their substrates. Selective estrogen-receptor modulators (SERDS) such 
as fulvestrant, is a pure agonist that promotes the nuclear degradation of the estrogen 
receptor (Er) via proteasomal proteolysis. When co-administered with the proteasomal
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 inhibitor bortezomib aggregation of nascent cytosolic Er is promoted activating the pro-
apoptotic mechanism of the UPR.1 Mediated by a series of chaperone complexes, similar 
drug-induced ubiquitination-degradation was observed when the tyrosine kinase inhibitor 
CI-1033 irreversibly alkylates a cysteine specific to the ErbB2/Her2 receptor.2 These 
examples bring specificity to their targets and mediate a global intracellular response 
significant enough to induct the UPS pathway through nonnative signaling. While they 
demonstrate the therapeutic potential of induced protein degradation, their utility is 
narrowed to the intrinsic nature of inhibitors rather than the synergistic exploitation of the 
UPS pathway. With the utility of the UPS pathway, a robust system that actively 
promotes the ablation of target proteins in an adaptable chemical-induced manner has yet 
to emerge.   
Several approaches to formulate a proteolytic-inducing small molecule system 
have shown promise. Crews and co-workers have developed a heterobifunctional small 
molecule capable of inducing proteasomal mediated protein degradation of multiple 
proteins of various cellular locations and capabilities. This PROTAC (PROteolysis 
TArgeting Chimera) only requires a targeting motif, rather than possessing any inhibitory 
action, and a ligand for and E3-ligase separated by a chemically inert linker. The 
PROTAC can then form a ternary complex joined by both the ligand specific POI and the 
E3-ligase. Thus, the multi-protein E3-ligase ubiquitin-promoting complex can actively 
sort and identify foreign substrates for ubiquitination and subsequent proteolysis. This 
adaptable system has been used to target and degrade the androgen and estrogen 
receptors, peptidase MetAP-2, the immune-regulator FKBP12, and the aryl hydrocarbon 
receptor using various E3-ligase specific ligands.3-7  
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Recently, a stimuli-responsive PROTAC was developed, where in response to 
mitogenic signaling, RTK dimerize and initiate a series of transautophosphyorylation 
events through their tyrosine residues within their intracellular domain. This event 
recruits a series of substrates that posses PTP and SH2 domains. This phosphoPROTAC 
(phosphate PROteolysis TArgeting Chimera) was designed to posses the phosphorylated 
tyrosine signaling domain from the NGF receptor, TrkA, and a VHL-binding sequence. 
The inactive phosphoPROTAC is phosphorylated by the RTK in response to mitogen 
activation. Once the phosphoPROTAC is activated it generates a binding site for the SH2 
or PTB-domain-containing effector protein of fibroblast growth factor receptor substrate 
2α (FRS2α) and is subsequently polyubiquinated and transported to the proteasome for 
proteolysis. Upon treatment of NGF-stimulated PC12 cells the authors observed roughly 
a 90% knockdown of the effector/substrate FRS2α.  
Encouraged by these results, the authors fabricated another phosooPROTAC 
capable of targeting the PI3K receptor using a peptidic sequence from the ErbB2 
receptor, which is phosphorylated by ErbB3 in response to neuregulin.8 This model 
produced dose-depended toxicity in MCF-7 cells and was successfully applied in a mouse 
xenograft model yielding a 40% reduction in tumor volume.8 Although these and the 
aforementioned PROTACS have proven to be effective modulators of protein 
degradation, they rely on the capability of the E2-ligase to transfer Ub to the POI. In the 
case where the ε-amino group is blocked or inactivated by surrounding residues, the E2 
ligase is incapable of Ub-conjugation. 
 A rapid and highly tunable method regulate intracellular concentrations of a 
specific protein involves the expression of fusion proteins coupled to an unstable degron-
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domain. With in the cell, the degron domain that remains unstable transfers this 
instability to its fusion partner. Upon exposure to a degron specific ligand, the domain is 
rescued and thus stabilized, whereas the absence of ligand facilitates its proteolysis.9, 10 
Although functionally useful, this system necessitates genetic intervention to supply 
protein degradation. In the past few years a novel application toward the development of 
direct ligand-mediated protein degradation has been introduced. Taking advantage of the 
general stabilizing factors that govern protein folding and internal cohesion, some groups 
have used various hydrophobic moieties conjugated to known potent inhibitors to pull 
down endogenous proteins.11,12 
 Interestingly, Hedstrom and co-workers have constructed a system that is capable 
of Ub-indpendent degradation by affixing a hydrophobic Boc3Arg group to the covalent 
(EA, ethacrynic acid) and non-covalent (TMP, trimethoprim) inhibitors of glutathione S-
transferase (GST) and E. coli dihydrofolatereductase (eDHFR), respectively. By 
mimicking an unfolded protein, through hydrophobic exposure, both EA and EA-
Boc3Arg inactivate GST. However, EA-Boc3Arg yielded a degradation effect, degrading 
roughly 80% of GST in whole cells, whereas TMP-Boc3Arg only achieved a 30% 
knockdown.11 The adaptable and tunable approach of mimicking hydrophobic exposure 
as a means of translational control has also been shown using fusion constructs, which 
possess a high affinity for a hydrophobic-tagged ligand (Figure 4.1).12 Under the auspice 
of the work performed by Hedstrom and co-workers, we sought to apply hydrophobic-
tagging against human thymidylate synthase (TS), a high value cancer target. In 
colorectal cancer (CRC), TS is overexpressed in the crypt cells of the gut where this de 
novo source of deoxythymidine monophosphate (dTMP) maintains large pools of
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Figure 4.1 General schematic for the hydrophobic tagging of stable proteins. 
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dTMP for DNA replication. This action has subsequently shown to yield routes of 
resistance to TS specific inhibitors in established cell lines making it difficult to 
manipulate its intracellular levels.13  
We previously established the insensitivity of TS against an RTX based 
PROTAC, which failed to demonstrate ubiquitination. Thus, investigating the potential of 
hydrophobic exposure through TS directed hydrophobically tagged ligand provided the 
means to avoid any dependency on either the conjugation or ligation enzymes of UPS. By 
working from a known TS inhibitor, raltitrexed, we synthesized a small array of 
hydrophobically diversified chemical tags to screen for potential RTX-based compounds 
that will recruit the cellular machinery responsible for identifying misfolded proteins and 
promote TS-proteasomal degradation. 
 
4.1 RESULTS AND DISCUSSION  
4.1.1 Induction of Hydrophobic Exposure to TS Structure Inherent  
In order to measure the response of TS to potential hydrophobic exposure, we 
induced two point mutations on the solvent exposed helices at residues R115 and D116 
(Figure 4.2). Single point mutations for both positions with tryptophan and isoleucine 
destabilized TS and decreased its half-life by 30%. However, double point mutation 
R115W/D116W and R115I/D116I decreased the half-life of TS by 90%. This level of 
degradation indicated that TS is responsive to aberrant hydrophobic exposure, thus 
establishing possibility that a TS targeting ligand with the proper level of hydrophobic 
exposure may induce proteasomal degradation. 
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Figure 4.2 Induction of hydrophobic exposure by site directed mutagenesis of TS 
(PDB 1HYV). The solvent exposed residues Arg115 and Asp116 were substituted for 
the hydrophobic amino acids Trp and Ille (yellow) in both single and double point 
mutations. The double R115W/D116W mutant demonstrated a significant instability 
with a 12-fold decrease in half-life as compared to wtTS (6 hrs). 
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4.1.2 Raltitrexed Dipeptide Analysis 
Quinazolinone based TS inhibitors rely on their poly-γ-glutamate metabolites for 
their increased intracellular residency and antitumor activity. It has been established that 
these metabolites are more potent inhibitors than their parent monoglutamate compounds. 
The addition of one glutamate residue on the γ-carboxyl of 2-desamino-2-methyl-N10-
propargyl-5,8-dideazafolic acid (ICI 198583) resulted in stronger binding to TS by 
approximately 30-fold.14 For these reasons we were interested in the potential inhibitory 
effect of raltitrexed (RTX, ICI D1695) in a similar manner. The crystal structure of the 
RTX•dUMP•TS complex shows the γ-carboxylate of RTX (1a) is coordinated through 
the hydrogen-bond network of water, which resides on the exterior of the binding pocket. 
Based on this observation, we designed a small set of RTX-dipeptides that would 
represent the various classes of amino acids: acidic (1b, RTX-Glu), basic (1c, RTX-Arg), 
hydrophobic-sterically restrictive (1d, RTX-Tyr), and hydrophobic-sterically 
unrestrictive (1e, RTX-Gly). Each conjugate was prepared under standard Fmoc solid 
phase peptide synthesis (SPPS) and their respective regioisomers were purified by HPLC. 
Enantiomeric purity of the conjugates was not considered of vital importance provided 
that neither stereocenter in the dipeptide affects TS analog fidelity or inhibition, only 
serum stability is, in this regard, of vital importance to inhibitor stability.  
To evaluate the potential inhibitory effects upon TS, incubation of each conjugate 
was performed over a 4-day time course in CHL-TS pJZ205 cells (Figure 4.3).  When 
compared to 1a, we found that both 1b and 1d produced a significant modulation in the 
inhibitory signature of TS with a moderate 5.5 and 14-fold increase in IC50 (Figure 4.3A). 
Conversely, both hydrophobic residues were considerably less effective than their
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Figure 4.3 (A) The relationship between the inhibitory characteristics (IC50) of free 1a 
and the γ-linked dipeptide conjugates 1b-e. (B) The relationship between the inhibitory 
characteristics (IC50) of free 1a and the α-linked dipeptide conjugates 1c’-e’. (C) 
General scheme for the synthesis of each α/γ-conjugate of 1a. 
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hydrophilic counterparts. Both 1c and 1e yielded a substantial 1450 and 3250-fold 
increase in IC50 values compared to 1a. Although not unanticipated for 1e as its 
calculated partition coefficient (LogP) was 0.77, indicating hydrophobic character, the 
similar result of 1c appeared to be unrelated to this same feature (calculated logP = -
1.01). The failure of these two dipeptides to assert any modest inhibitory action could be 
for a number of reasons: (i) the hydrophobic character prevented uptake by the RFC, (ii) 
without a free γ-carboxylate, neither is a substrate for FPGS, thus their cellular retention 
is compromised, and (iii) their direct binding with TS is obstructed due to their anti-polar 
nature or steric bulk. Interestingly, when we profiled the α-dipeptide conjugates of 1a, 
we found a substantial inhibitory effect for all compounds (Figure 4.3B).  
We reasoned that the drastic suppression in IC50 values could not confer the 
failure of 1c and 1e as a result of impaired reduced folate carrier (RFC) uptake; rather, 
the positional modification of the α-carboxylate may have allowed for FPGS processing 
at the γ-position, thus reinstating polyglutamylation. However, previous research with 
methotrexate dipeptides revealed the significance behind the role of the α-carboxylate.15 
In order to be a substrate for FPGS, the terminal α-carboxylate must be present regardless 
of the condition of the initial α-carboxylate.15 Given this evidence, it’s therefore 
reasonable to deduce that the enhanced suppressive effect of the α-conjugates is not due 
to FPGS processing. 
The potency for compound 1d and 1d’ is believe to stem from targeting both TS 
and FPGS, although the later is unlikely to target FPGS due to the occlusion of its 
terminal α-carboxylate. Previous research has shown that modification of quinazolinone -
based inhibitors with ornithine act as powerful inhibitor of FPGS and TS.16, 17  
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4.1.3 Biological Evaluation of Di-,Tri-, and Tetraglutamates of Raltitrexed 
The intracellular metabolism activity of 1a plays a distinct role in both its cellular 
residence and substrate avidity. It has been shown that that successive intracellular 
glutamylation by FPGS of 1a occurs with 90% conversion to the mono-, di-, tri-, and 
tetraglutamates being formed within the first 30 minutes of exposure.  The reported 
amount of material lost was approximately 30% with the remaining undergoing further 
processing to tetra-, penta-, and to a lesser extent, hexaglutamates.18  
Based on these results, we synthesized the di-, tri-, and γ-tetraglutamates (1a, 2a, 
and 2c, respectively) using standard SPPS followed purification by HPLC. To analyze 
their potential to serve as a possible scaffold for hydrophobic tagging, we examined each 
conjugates’ TS binding ability and pharmacological impact in CHL-TS pJZ205 cells and 
respective lysates (Figure 4.4 and 4.5). Inhibition analysis of 1a, 2a, and 2c showed a 
trending increase in resistance as glutamate addition progressed with 2c potency 
decreasing 232 fold (Figure 4.4A).  
However, the triglutamate conjugate, 2a, resisted this trend and maintained its 
potency. Isothermal titration calorimetry correlated with the inhibition analyses and 2a 
did not deviate from the inhibition characteristics of the parent monoglutamate (1a). 
Finally, the half-life of each conjugate was assessed to determine if the each conferred 
the stabilizing effect of 1a. None of the conjugates transformed the extreme stabilization 
to the extent of 1a. The di- and tetraglutamate showed marginal reduction the half-life 
status of TS with a 2 and 2.4 fold increase in half-life, respectively, with conjugate 2a 
reporting a 1.7 fold increase (Figure 4.5). 
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Figure 4.4 (A) The effect of conjugating one, two, and three γ-linked glutamic acid 
residues upon 1a as measured by the binding ability (Kd) and growth inhibitory 
characteristics (IC50) in CHL-TS pJZ205 cells. (B) The effect between α and γ 
regiochemistry between the triglutamates 2a and 2b of 1a as measured by growth 
inhibition (IC50) in CHL-TS pJZ205 cells. (C) Values of each conjugate measured 
against the fold change of 1a. 
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Figure 4.5 The relationship between the stability of TS and the effect of successive γ-
glutamylation on 1a. (A) Western blot analyses as measured by the half-life in CHL-TS 
pJZ205 cells of di- (RTX-E), tri- (RTX-EE), and tetraglutamates (RTX-EEE) of 1a. 
(B) Graphical representation of TS stability (red) against di- (blue), tri- (green), and 
tetraglutamates (black) of 1a. (E = γ-glutamic acid) 
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To examine the stability of regioisomers between di- and triglutamate conjugates, 
we prepared a α-connected triglutamate and assessed its impact on in vitro inhibition of 
TS (Figure 4.4B). The α-triglutamate conjugate 2b potency reverted to that of the 
diglutamate 1b, highlighting the innate importance of the regiochemical linkage between 
residues two and three in the triglutamate conjugate and its relationship to in vitro 
efficacy. Furthermore, the biophysical measurements of all conjugates were evaluated to 
determine the major driving force behind the stability of 1b (Figure 4.6).  
As shown in Figure 4.6, both panels A and B show favorable relationships 
between the thermodynamic reaction potential (ΔG) and the general order and alignment 
of van der Waals and hydrogen bonding (ΔH) of the RTX conjugates to TS. Maximum 
ligand alignment is evidenced by their observed exothermic behavior (ΔH < 0), which 
reflects the correct placement of the conjugate at the binding interface (Figure 4.6B). 
However, entropic forces become non-ideal as the as the final glutamate or isoleucine 
unit is appended to the triglutamate conjugate (Figure 4.6C). This is likely a consequence 
chain extension, which increases the disordered nature of chain as residues are added. 
Hence, the entropic costs for binding these extended conjugates is high.19 
 
4.1.4 Safety-Catch SPPS Synthesis of Raltitrexed-Triglutamate-Hydrophobic Tags 
Based on our synthetic efforts with polyglutamylation of 1a, we were interested in 
building a small library of hydrophobic-tagged compounds with 2a serving as the main 
scaffold-binding unit.  However, given that traditional Fmoc SPPS methods build from 
the amino to the carboxy-terminus, the ability to construct a library based on 2a was 
prohibitive. As such, we investigated the potential of the Kenner “Safety-Catch” solid
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Figure 4.6 Biophysical analyses of raltitrexed conjugates by isothermal titration calorimetry against TS and dUMP. (A) The 
calculated change in Gibbs free energy (all are exergonic, ΔG < 0), (B) measured change in enthalpy (all are exothermic, ΔH < 0), 
and (C) the calculated change in entropy for the binding of each conjugate to the dUMPTS complex, respectively. The 
transformation from RTX-EE to RTX-EEE illustrates the increase in disorder (ΔS > 0) as related to their binding and their increase 
in length and size (PgA), which follows a concomitant decrease in enthalpy for those conjugates (B, C).  
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phase support (Figure 4.7).20 The alkanesulfonamide handle was quantitatively charged to 
high loading aminomethyl resin using commercially available 3-
carboxypropanesulfonamide. Gram quantities for the Safety-Catch (5) resin were 
prepared using standard DICI (N,N’-diiso-propylcarbodiimide) and HOBt (N-
hydroxybenzotriazole) coupling conditions monitored by a bromophenol blue test (Figure 
4.8).21 Linker oligomerization does not occur as the alkanesulfonamide linker is 
unreactive to HOBt esters.22 Optimization of the first Fmoc-Glu-OtBu with high loading 
efficiency was initially preformed at low temperatures with PyBOP 
[bromotris(pyrrolidino)phosphonium hexafluorophosphate] and a tertiary base i-Pr2EtN 
(Diispropylethylamine) as acylation with HATU reportedly leads to significant levels of 
racemization.22  
Loading efficiencies for coupling of the first Fmoc-Glu-OtBu (6) produced 
extremely low yields for the first charge, with no improvement upon a second charge. 
Continued efforts to increase yields were examined by increasing the reaction 
temperature to -20 °C from -40 °C, using DMF to fully swell the resin, and increasing the 
equivalents of PyBOP and Fmoc-(GluOtBu) (Table 4.1, entry 2). Additional efforts were 
made to maintain the swelling properties of the resin using DMF with reaction volume 
restriction did not abrogate the low yields. Questioning the reactivity of our 
alkanesulfonamide support we switched to commercial Aryl safety-catch resin, however, 
results did not improve (Table 4.1, entry 3) 
Although reports state that the active intermediate during coupling with PyBOP at 
low temperature is the O-acyl phosphonium adduct, we found that coupling to an 
extended methylene bridged carboxylate did not warrant low temperatures.23 We then
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Figure 4.7 General scheme for the Kenner safety-catch resin and the alkanesulfonamide linker (1) with subsequent acylation (2), 
activation (3) and release of the peptide conjugate through nucleophilic displacement by a potent primary amine (4). 
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Figure 4.8 General scheme for building raltitrexed triglutamate scaffold. (i & ii) FMOC-Glu-OtBu (8 eq), PyBop (8 eq), DIPEA 
(14 eq), RT, 15 hrs;  (iii) 50% piperdine in DCM, 3x 5-10 mg 1 hr Abs @ 301 nm; (iv) RTX (5 eq), PyBOP (5 eq), DIPEA (10 eq), 
2-4 hrs (v) ICH2CN (20 eq) in NMP, RT, 24 hrs; (vi) 5 eq of HyT in 5% DMF in THF, 25 °C, 16 hrs. (1a, RTX = raltitrexed) 
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Table 4.1 Preliminary Safety-Catch reaction parameters. Abbreviations: AlkaneS = Alkanesulfonaminde; ArylS: 
Arylsulfonaminde; DIPEA = diisopropylamine; CHCl3 = chloroform; DMF = N’,N’-dimethylformamide; RT = room temperature; 
N/A = not applicable; DICI = N,N’-diisopropylcarbodiimide; HOBt = N-hydroxybenzotriazole; PyBOP = 
bromotris(pyrrolidino)phosphonium hexafluorophosphate. 
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compared the same reactions using 0.044 mmol of resin under both -20 °C and room 
temperature to generate a 13% and 58% yield, respectively (Table 4.1, entry 4). The 
reaction was duplicated and charged twice to improve yields to 68% (Table 4.1, entry 7). 
Given the moderate increase in substitution, entry 4 was examined for additional 
coupling followed by Fmoc cleavage (7) managed to stabilize coupling yields (57%) 
(Table 4.1). Further optimization was not carried out and raltitrexed (8) was coupled 
under lower equivalents followed by ICH2CN activation (9). The conjugate was cleaved 
from the resin using 1 equivalent of PgA to yield pro-RTX-EE-PgA (43%).  
Encouraged by our improvements, we decided to use the Quest210 synthesizer to 
meet our combinatorial needs. Our initial attempt at primary coupling of Glu-OtBu-OH 
was met with low yields (~20%), although a second and third charge elevated coupling 
up to 87% (Table 4.2, entries 10a-d). In order to improve coupling efficiency for the 
attachment of the second glutamic acid the incubation time was increased to 27 hours. 
The first round of the second attachment improved average yields to 37%, however a 
second charge did not alter coupling (Table 4.2 entries 11a-d).  
Low yields were not suitable for further advancement to generate hydrophobic-
tagged library, thus the reaction capacity was increased 5-fold to 0.6 mmol batch 
reactions. A dramatic improvement in yield and a reduction in charging, from three to 
two, resulted for both glutamate residues (Table 4.2, entries 12 and 13). 
 
4.1.5 Pilot Study for Safety-Catch Raltitrexed-Triglutamate-Hydrophobic Tags 
A small pilot library was constructed using seven various hydrophobic tags fitting 
with active primary amines based on their known reactivity’s, boiling points, and their
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Table 4.2 Safety-Catch reaction parameters for Quest210. Abbreviations: AlkaneS-E = Alkanesulfonaminde-GluOtBu-OH; 
AlkaneS-EE = Alkanesulfonaminde-[GluOtBu-OH] (×2); DIPEA = diisopropylamine; DMF = N’,N’-dimethylformamide; RT = 
room temperature; N/A = not applicable; DICI = N,N’-diisopropylcarbodiimide; HOBt = N-hydroxybenzotriazole; PyBOP = 
bromotris(pyrrolidino)phosphonium hexafluorophosphate; RTX = raltitrexed. 
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calculated partition coefficients (logP) (Figure 4.9A). Each was activated for 24 hrs, 
washed and displaced with nucleophile/hydrophobic tags 1-7 (HyT1-7) and purified by 
HPLC. A parallel synthesis, performed by our colleague, using selective amidation 
methods previously developed by our lab, yielded three highly pure γ-selective 
hydrophobic-tagged raltitrexed-conjugates with various polyethylene glycol (PEG) 
linkers (Figure 4.9B).  
These conjugates were produced to measure the general nature of the glutamic 
acid bridge, however, ITC analyses of the three conjugates failed to produce any 
thermodynamic results when challenged against the dUMPTS complex (data not 
shown). This strongly suggests the ability, if any, of HyT(9-11) to produce a binding 
event or exhibit any inhibitory is not promoted by any enthalpic promoted mechanism.   
 
4.1.6 Biological Evaluation of Hydrophobic-Tagged Raltitrexed 
 The biological impact of RTX-HyT(1-10) were examined over a 4-day time 
course in CHL-TS pJZ205 cells (Figure 4.10). Conjugates prepped using the both the 
safety-catch resin and selective amidation reported elevated IC50’s, exceeding their parent 
compounds (2a and 1a, respectively) cellular efficacy by an average of 2.5×106 fold. 
Compounds HyT(7) and HyT(8) produced the lowest inhibition values of 2.3 and 3.7 µM 
as shown in figures 4.10A and 4.10B.  
The inhibition values were followed up with a half-life assay to determine if the 
either of the conjugates had promoted TS destabilization through mimicked hydrophobic 
exposure (Figure 4.11). Compound HyT(9) produced a half-life of approximately 14 
hours, 1.3 fold higher than the DMSO vehicle (wtTS). However, when compared to 2a
 128 
 
 
Figure 4.9 (A) Hydrophobic tags (HyT) used for pilot study with RTX-EE Kenner 
safety-catch resin with alkanesulfonamide linker. (B) RTX-PEGn-HyT synthesized via 
DCC/DMAP coupling with various pegylated linkers.  
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Figure 4.10 Growth inhibition analyses of RTX conjugates with HyT’s 5-7 and 8-10 
with triglutamate (A) and pegylated linkers (B), respectively.  
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Figure 4.11 (A) Western-blot analysis of RTX-PEG6-HyT(8) half-life. (B) Graphical 
representation of the half-life of raltitrexed (blue), RTX-PEG6-HyT(8) (black), and 
wtTS DMSO vehicle (red). 
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the effect HyT(9) displays is casually lower, indicating its action is the result of TS 
destabilization. Additional input in necessary to determine if HyT(9) activity can impose 
dose-dependent degradation and if this effect is linked to the proteasome. 
 
4.1.7 Advanced Study for Safety-Catch Raltitrexed-Triglutamate-Hydrophobic Tags 
 The preliminary results of the pilot study encouraged the development of larger 
in-depth analysis, which examined the spatial nature of the HyT’s and their respective 
inherent physical properties (logP) and inhibitory capacities (IC50) against TS (Table 4.3). 
Group I was predicted to demonstrate an inhibitory relationship directly proportional to 
its chain length (logP) due to the increase in potential hydrophobic surface area (Figure 
4.12). However, this relationship was not observed, rather HyT(4), the methylated γ-
carboxylate, yielded the lowest IC50.  
Interestingly, HyT(11) with its 9-methylene chain, also produced and IC50 
resembling 1b (Figure 4.4). The inhibitory impact by HyT(4) is likely due to the modest 
alteration. However, the response to HyT(11) may have maintained the low inhibition 
threshold of 1b due to its chain extension, which may not interact directly with the 
surface of TS, but allows for surface recognition for degradation. Additional studies 
determining each tags roll in degradation is needed.  
Further analysis of group II and III compared the effect of methylene spacers (1, 
2, or 3) and the effect of benzylic heteroatoms (HyT(19)), along with electron 
withdrawing (EWG) and donating groups (EDG), HyT(17, 22) and HyT(18, 21), 
respectively. Hydrophobic tags 7, 18, and 20 demonstrated poor inhibition with values 
exceeding 10 µM (Figure 4.12). Interestingly, HyT(19), HyT(22), and HyT(23) showed
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Table 4.3 List of corresponding HyT’s used to synthesize their respective RTX-EE-
HyT(n) conjugates. Yields are based on spectrophotometric measurement of RTX 
(1a). Inhibition was measured after 48 hrs in CHL-TS pJZ205 cells. (N/A: Not 
Available)  
 133 
 
 
Figure 4.12 Structural relationship between HyT’s conjugates (RTX-EE-HyT(n)) with 
their partition coefficients (logP) and inhibitory capacity toward TS (IC50). (N/A: Not 
Available) 
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similar results to that of HyT(4) and HyT(11). Hydrophobic tags 22 and 23 indicated that 
spacer length might be critical to inhibition when compared to HyT(7), HyT(17), and 
HyT(20) with the optimal length set at 2 methylene units (Table 4.12, II and III). 
Moreover, strong intra-chain-EDG’s, HyT(21), may also play a role in muting 
hydrophobic response. The EDG and EWG of benzylic (single methylene spacers) tags 
appear to be deleterious (HyT 17 and 18) with IC50’s reported greater than 5 µM. 
Groups V hydrophobic tags possessed some of the lowest IC50’s when compared 
to 1b and the other group’s intra-inhibitory results. Here, their “spherical” nature, rather 
than the aromaticity displayed by members groups III and IV, appears to parallel their 
respective partition coefficients (Table 4.12, V). Although aromatic, the dual nature of 
biphenyl moiety of HyT(16) seems to be beneficial and may override its single aryl 
homolog HyT(7). Lastly, group VI, a series of potential CuAAC conjugates, and a cyano-
terminated aliphatic amine offer modest results with 2× the inhibitory capacity of 1b. 
Although it should be noted that HyT(13) does have a surprisingly low IC50 when its 
hydrophilic partition coefficient is taken into consideration.  
While many of these conclusions are based on the structural activity relationship 
(SAR) between the architecture of the hydrophobic tag and both its theoretical logP and 
observed IC50, it should be noted that additional analyses should be performed to 
substantiate the preliminary SAR. The development of the 1b scaffold, its biological 
evaluation, and the construction of the HyT library do, however, provide a useful insight 
for further investigation to the degradative potential of hydrophobic tags upon 
thymidylate synthase.  
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4.2 EXPERIMENTAL 
4.2.1 General Cell Preparation 
All cells were provided by Dr. Franklin G. Berger (University of South Carolina, 
Department of Biological Sciences). Cells were grown in a T75 flask under 10% fetal 
bovine serum (FBS) in high glucose Dulbecco's Modified Eagle's medium (DMEM) with 
100 U of penicillin-streptomycin (Pen-Strep) at 37 °C and humidified at 5% CO2. Cell 
line RJK33.13, a TS-deficient derivative of V79 Chinese hamster lung cells (CHL-TS 
pJZ205, CHL-TS pJZ205/200) were grown to confluency and passaged at either 1:10 or 
1:20 with 0.25% trypsin.24 
 
4.2.2 TS Half-Life Studies 
The half-life of thymidylate synthase in RJK33.13 cells under exposure to HyT(9) 
was assessed according to the protocol previously reported.25 The half-life of the 
conjugates 1a, 2a, and 2c was generously performed by Karen Barbour (University of 
South Carolina, Department of Biological Sciences).  
 
4.2.3 Growth Inhibition Studies 
The growth inhibition response of all compounds, unless otherwise stated, was 
assessed according to the protocol previously reported.13 This work was generously 
performed by Karen Barbour (University of South Carolina, Department of Biological 
Sciences). The growth inhibition of RTX-EE-HyT 1-7 and 11-23 in CHL-TS pJZ205 cells 
was calculated after 48 hours of triplicate drug conjugate incubation at 37 °C with 5% 
humidity using CyQuant Direct Cell Proliferation Assay (Life Technologies, P/N 
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C35011). Inhibition analysis was implemented per the manufactures instructions unless 
otherwise noted and calculated using Prisim 6 Trial Software. 
 
4.2.4 Solid Phase Peptide Synthesis of Raltitrexed Glu, Gly, Arg, and Tyr Conjugates 
Unless otherwise noted, all reactions were carried out using an Argonaut Quest 
210 Organic Synthesizer. The following stoichiometric parameters were followed for all 
reaction: to a 5 mL reaction cartridge was added Wang-aminoacid-Fmoc (0.05 mmol) 
and 4 mL of DMF. The resin was allowed to swell for 60 minutes before it was drained 
and deprotected in 20% piperidine in DMF followed by agitation 45 min after which a 
second Kaiser test was performed.26 The resin was then filtered and washed with DMF (3 
× 5 mL) and filtered again. RTX (1a) (4.0 eq, 0.20 mmol) was dissolved in 5 mL of DMF 
with HBTU (2.9 eq, 0.145 mmol), HOBt (2.9 eq, 0.145 mmol), NMM (4.0 eq, 0.20 
mmol) then added to the reaction. The reaction was agitated for 2 hrs then filtered and 
washed with DMF (3 × 5 mL) then MeOH (1 × 5 mL) and dried.  
Raltitrexed-peptide conjugates were liberated from the resin under 2 mL of 98% 
TFA in water for 2 hrs. The resin was drained and the eluent was collected. The resin was 
washed again in 5 mL of 98% TFA in water then pooled and dried under N2 until a 
yellow film appeared. To the flask was added ice-cold diethyl ether to form a precipitate. 
The precipitate was centrifuged at 9,000 RPMs at 4 °C for 10 min. The clear eluent was 
decanted the remaining material was lyophilized overnight to yield the crude forms of 1b 
(18.6 mg, 36.0 µmol), 1e, (30.7 mg, 49.4 µmol) 1c (25.5 mg, 40.9 µmol), and 1d (25.1 
mg, 40.8 µmol). Each crude was purified by HPLC using a 250 × 10-mm, 5 µm RP C18 
column at 5 mL min-1 from 10-65% ACN in 0.1% TFA for 65 min. Injections of 1.0 mL 
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were monitored at 269 and 341 nm. Fractions were pooled, concentrated, and lyophilized. 
Purified products were characterized using ESI LCMS over 150 × 2.0-mm, 3 µM RP C18 
over 10-65% ACN (0.1% formic acid) gradient in 45 min. Purified γ-products 1b (1.1 
mg, 5.2%), 1e (2.3 mg, 7.5%) 1c (1.2 mg, 5.7%), and 1d (1.2 mg, 4.8%) and their 
corresponding Purified α-products 1b’ (1.1 mg, 5.2%), 1e’ (3.4 mg, 11.1%) 1c’ (1.2 mg, 
5.7%), and 1d’ (1.4 mg, 5.6%) were identified at [M+H]+ 588, 623, 516, and 616 m/z by 
ESI LCMS.  
 
4.2.5 Solid Phase Peptide Synthesis of Di-, Tri-, and Tetraglutamates 
To a 20 mL reactor cartridge was added Wang-GluOtBu-Fmoc resin (101 mg, 
0.05 mmol) followed by solvation in DMF. A fresh solution of 20% piperidine in DMF 
was added to the reactor and agitated for 30 min. The resin was then filtered and washed 
with DMF (3 × 5 mL) and filtered again. The following is the general procedure for each 
Fmoc-GluOtBu acid coupling: To separate 50 mL flask was added Fmoc-GluOtBu (4.0 
eq, 0.20 mmol), HBTU (2.9 eq, 0.146 mmol), HOBt (2.9 eq, 0.146 mmol), NMM (4 eq, 
0.2 mmol). The reagents were dissolved in 10 mL of DMF, transferred to the reaction 
cartridge and agitated for 45 min. The resin was then filtered and washed with DMF (3 × 
5 mL) and filtered again. A Kaiser test was administered to determine reaction 
completion.26  
To a separate vial, 1a (4.0 eq, 0.20 mmol) was dissolved in 10 mL of DMF 
followed by HBTU (2.9 eq, 0.146 mmol), HOBt (2.9 eq, 0.146 mmol), and NMM (4 eq, 
0.2 mmol) and then added to the reactor cartridge. The reaction was agitated for 2 hrs 
then filtered and washed with DMF (3 × 5 mL) then MeOH (1 × 5 mL) and dried in 
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vacuo for 45 minuntes. Raltitrexed-Glu conjugates were liberated from the resin under 10 
mL of TFA for 45 minutes. The resin was drained and the eluent was collected. The resin 
was washed again in 5 mL of TFA then pooled and dried under N2 until a yellow film 
appeared. To the flask was added ice-cold diethyl ether to form a precipitate and was 
stored at -20 °C for 30 min. The precipitate was centrifuged at 9,000 RPMs at 4 °C for 10 
min.  
The clear eluent was decanted the remaining material was lyophilized overnight 
to yield the crude forms of 1b (24.2 mg, 41.2 µmol), 2a, (33.2 mg, 46.7 µmol), 2c (29.7 
mg, 35.1 µmol), 2b (12.8 mg, 17.8 µmol). Each crude was was purified by HPLC as 
previously mentioned in 4.2.3. Purified γ-products were 1b (6.5 mg, 27.3%), 2a, (4.8 mg, 
14.3%), 2c (29.7 mg, 12.1%), 2b (3.8 mg, 29.8%) and identified by LCMS as noted in 
section 4.2.4 by their [M+H]+ 588, 717, 846, and 717 m/z.  
 
4.2.6 Safety-Catch Resin and RTX-EE-HyT Conjugates 
The synthesis of the safety-catch alkane sulfonamide linker and all pilot RTX-EE-
HyT conjugates were performed according to the protocols previously reported.22 
Reactions carried out for Table 4.1 were completed in a 50 mL round bottom glass 
whereas all reactions in Table 4.2 were performed on an Argonaut Quest 210 Organic 
Synthesizer.  
The advanced Safety-Catch study was performed as previously reported with 
various alterations.27 Briefly, using the alkanesulfonamide linker from the pilot study, we 
successively built the RTX-EE platform and prepared approximately 50 mg (0.020 
mmol) for activation (ICH2CN (20 eq), DIPEA (40 eq) in NMP, RT, 24 hrs, no light) and 
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release with 5 eq (0.10 mmol) of each HyT’s 1-7 and 11-23 at RT for 64 hrs. Free amines 
were captured with high loading tosyl chloride resin (125 mg, 0.3 mmol) and Et3N (84 
µL, 0.60 mmol) per reaction in 1 mL of DCM and agitated on an orbital shaker at 150 
RPM’s overnight at 27 °C.  
The triethylamine salts were free based with K2CO3 (5.2 mmol, 700 mg) for 15 
hours at 33 °C at 150 RPM’s. The salts were gravimetrically filtered and washed with 
DCM. The filtrates were dried in vacuo, resuspended in 2 mL of Xylene and washed with 
2 mL of acetone and filtered again. The filtrate was dried in vacuo and washed with 2-4 
mL of BuOH and dried again until dry.  
Protecting groups were cleaved with TFA/H2O/TIPS [95:0.5:0.5] for 1 hour then 
dried under N2 for 20 minutes. The conjugates were resuspended in 1 mL of 10% ACN in 
water then diluted at 1:25 in 100 µL of DMSO. Each conjugate was quantitated by 
UV/Vis based on the adsorption of RTX at both 269 and 341 nm, respectively. The bulk 
filtrates in 10% ACN in water were subsequently lyophilized, massed, and their yields 
calculated (Table 4.3) followed by their resuspension in DMSO to yield a 10 mM 
solution of each conjugate for biological evaluation.  
 
4.2.7 Safety-Catch Resin and RTX-PEGn-HyT Conjugates 
The synthesis of the RTX-PEGn-HyT conjugates was performed by our colleague, 
Enoch Adogla, under Dr. Qian Wang’s mentorship (Department of Chemistry and 
Biochemistry, University of South Carolina). 
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4.2.8 Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) was performed on a VPITC instrument 
(Microcal Corp.) with a 250 µL syringe. All ITC measurements were carried out at in 
degassed solutions at 26 °C. Approximately fifty-two, 5 µL injections were made with 6-
second duration and 120 seconds spacing. The macromolecule (TS) concentration was 15 
µM in 50 mM Tris-HCl, pH 7.4 with 1 mM EDTA and 20 µM BME, which is referred to 
as “Buffer A.” Titration was carried out in buffer A with the following reagents: 100 µM 
dUMP and 300 µM of conjugate(s). The data was processed using the manufactures 
software ORIGIN. 
 
4.3 REFERENCES  
1. Ishii, Y. et al. Bortezomib Enhances the Efficacy of Fulvestrant by Amplifying 
the Aggregation of the Estrogen Receptor, Which Leads to a Proapoptotic 
Unfolded Protein Response. Clin. Cancer Res. 17, 2292-2300 (2011). 
2. Citri, A. et al. Drug-induced ubiquitylation and degradation of ErbB receptor 
tyrosine kinases: implications for cancer therapy. Embo J. 21, 2407-2417 (2002). 
3. Sakamoto, K.M. et al. Protacs: Chimeric molecules that target proteins to the 
Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. 
Sci. U. S. A. 98, 8554-8559 (2001). 
4. Sakamoto, K.M. et al. Development of protacs to target cancer-promoting 
proteins for ubiquitination and degradation. Mol. Cell. Proteomics 2, 1350-1358 
(2003). 
 141 
5. Schneekloth, J.S. et al. Chemical genetic control of protein levels: Selective in 
vivo targeted degradation. J. Am. Chem. Soc. 126, 3748-3754 (2004). 
6. Bargagna-Mohan, P., Baek, S.H., Lee, H., Kim, K. & Mohan, R. Use of 
PROTACS as molecular probes of angiogenesis. Bioorg. Med. Chem. Lett. 15, 
2724-2727 (2005). 
7. Puppala, D., Lee, H., Kim, K.B. & Swanson, H.I. Development of an aryl 
hydrocarbon receptor antagonist using the proteolysis-targeting chimeric 
molecules approach: A potential tool for chemoprevention. Mol. Pharmacol. 73, 
1064-1071 (2008). 
8. Hines, J., Gough, J.D., Corson, T.W. & Crews, C.M. Posttranslational protein 
knockdown coupled to receptor tyrosine kinase activation with 
phosphoPROTACs. Proc. Natl. Acad. Sci. U. S. A. 110, 8942-8947 (2013). 
9. Banaszynski, L.A., Chen, L.C., Maynard-Smith, L.A., Ooi, A.G.L. & Wandless, 
T.J. A rapid, reversible, and tunable method to regulate protein function in living 
cells using synthetic small molecules. Cell 126, 995-1004 (2006). 
10. Pratt, M.R., Schwartz, E.C. & Muir, T.W. Small-molecule-mediated rescue of 
protein function by an inducible proteolytic shunt. Proc. Natl. Acad. Sci. U. S. A. 
104, 11209-11214 (2007). 
11. Long, M.J.C., Gollapalli, D.R. & Hedstrom, L. Inhibitor Mediated Protein 
Degradation. Chem. Biol. 19, 629-637 (2012). 
12. Neklesa, T.K. et al. Small-molecule hydrophobic tagging-induced degradation of 
HaloTag fusion proteins. Nat. Chem. Biol. 7, 538-543 (2011). 
 142 
13. Barbour, K.W. & Berger, F.G. Cell death in response to antimetabolites directed 
at thymidylate synthase. Cancer Chemother. Pharmacol. 61, 189-201 (2008). 
14. Jackman, A.L. et al. The Biochemical Pharmacology of the Thymidylate Synthase 
Inhibitor, 2-Desamino-2-methyl-N-10-Propargyl-5,8-dideazafolic acid (ICI-
198583). Biochem. Pharmacol. 42, 1885-1895 (1991). 
15. Moran, R.G., Colman, P.D., Forsch, R.A. & Rosowsky, A. A Mechanism for the 
Addition of Multiple Moles of Glutamate by Folylpolyglutamate Synthaetase. J. 
Med. Chem. 27, 1263-1267 (1984). 
16. Singh, S.K. et al. Symthesis and Biological Evaluation of N-alpha-(5-deaza-
5,6,7,8-tetrahydropteroyl)-L-Ornithine. J. Med. Chem. 35, 2002-2006 (1992). 
17. Rosowsky, A., Forsch, R.A. & Moran, R.G. Inhibition of folylpolyglutamate 
synthetase by substrate analogues with an ornithine side chain. J. Heterocycl. 
Chem. 33, 1355-1361 (1996). 
18. Gibson, W. et al. The Measurement of Polyglutamate Metabolites of the 
Thymidylate Synthase Inhibitor ICI-D1694, In Mouns and Human Cultured-Cells. 
Biochem. Pharmacol. 45, 863-869 (1993). 
19. Kamb, A., Moore, J.F., Calvert, A.H. & Stroud, R.M. Structural Basis for 
Recognition of Polyglutamyl Folates by Thymidylate Synthase. Biochemistry 31, 
9883-9890 (1992). 
20. Kenner, G.W., McDermot.Jr & Sheppard, R.C. Safety Catch Principle in Solid 
Phase Peptide Synthesis. Journal of the Chemical Society D-Chemical 
Communications, 636-637 (1971). 
 143 
21. Krchnak, V., Vagner, J., Safar, P. & Lebl, M. Amino-Acids and Peptides .206. 
Nonivasive Continous Monitoring of Solid-Phase Peptide-Synthesis by Acid-Base 
Indicator. Collect. Czech. Chem. Commun. 53, 2542-2548 (1988). 
22. Backes, B.J. & Ellman, J.A. An alkanesulfonamide "safety-catch" linker for solid-
phase synthesis. J. Org. Chem. 64, 2322-2330 (1999). 
23. Kim, M.H. & Patel, D.V. BOP as a Reagent for Mild and Efficient Preparation of 
Esters. Tetrahedron Lett. 35, 5603-5606 (1994). 
24. Nussbaum, R.L., Walmsley, R.M., Lesko, J.G., Airhart, S.D. & Ledbetter, D.H. 
Thymidylate Synthase-Deficient Chinese-Hamster Cells - A Selection for Human-
Chromosome 18 and Experimental System for the Study of Thymidylate Synthase 
Regulation and Fragile-X Expression. Am. J. Hum. Genet. 37, 1192-1205 (1985). 
25. Pena, M.M.O., Xing, Y.Y., Koli, S. & Berger, F.G. Role of N-terminal residues in 
the ubiquitin-independent degradation of human thymidylate synthase. Biochem. 
J. 394, 355-363 (2006). 
26. Kaiser, E., Colescot.Rl, Bossinge.Cd & Cook, P.I. Color Test for Detection of 
Free Terminal Amino Groups in Solid-Phase Synthesis of Peptides. Anal. 
Biochem. 34, 595-& (1970). 
27. Backes, B.J., Harris, J.L., Leonetti, F., Craik, C.S. & Ellman, J.A. Synthesis of 
positional-scanning libraries of fluorogenic peptide substrates to define the 
extended substrate specificity of plasmin and thrombin (vol 18, pg 188, 2000). 
Nat. Biotechnol. 18, 559-559 (2000). 
 
 144 
CHAPTER 5 
 
5.0 SUMMARY AND CONCLUSION 
Here, we described two approaches’ to systematically degrade human thymidylate 
synthase through both an ubiquitin-dependent and independent mechanism. Through our 
synthetic endeavors (Table 2.2), we were able to characterize and develop a raltitrexed 
(RTX) γ-selective TS-specific probe and pursue in vitro TS tracking through the in situ 
application of CuAAC chemistry (Figure 2.12 and 2.14). Applying our previous synthetic 
approaches, we used the TS-specific antifolate raltitrexed to synthetically construct a TS-
HIFα heterobifunctional ligand (PROTAC-1 and -2) that would bind to TS and recruit 
the VHL E3-ligase complex for proteasomal degradation. It was hypothesized that 
PROTAC-1 and/or -2 would engender the polyubiquitination of TS necessary to induce 
ubiquitin-dependent proteasomal degradation. This strategy was perceived to be superior 
to the direct systemic administration of antimetabolites used to pharmacologically inhibit 
TS action and function independently of the internal TS degron.  
We found that neither PROTAC-1 or -2 enabled the targeted ubiquitination of TS, 
rather, only moderate inhibition (0.20 µM IC50) of the TS ternary complex (PROTAC-
1•dUMP•TS) was achieved with half-life stabilities resembling those of free RTX (Half-
Life > 24 hrs). The failure of our PROTAC to systematically degrade (through 
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ubiquitination) TS could potentially be the result of: (i) the relative short length of the 
linker, both triglycine and PEG, may have restricted the presentation of the HIFα signal 
peptide and allowed for its non-specific interaction with the surface of TS, (ii) the 
regioselectivity of RTX to the linker may have impaired the ability of RTX to 
successfully dock with TS as only the γ-carboxylate of RTX has been shown to yield high 
binding affinity, or (iii) the lack of active surface lysine moieties on TS has likely 
rendered PROTAC’s a moot endeavor, whereas if the VHL E3-ligase were recruited, the 
absence of a viable ligation partner (ε-amino group) for the E2-conjugating enzyme 
would not accommodate proteasomal degradation via the UPS.  
However, the PROTAC served as a translational probe of the innate properties of 
TS degradation. Previous results have shown TS degradation is independent to Ub even 
the conditions of TS lysine-null mutant. Our results corroborate the inherent resistance of 
TS to Ub and substantiate its status as proceeding via ubiquitin-independent proteasomal 
degradation.   
Notwithstanding, we sought to explore an alternate approach to ligand-directed 
degradation of TS. We hypothesized that appending a hydrophobic moiety or “tag” to 
raltitrexed functionalize RTX to act as a direct post-translational degradation ligand, 
whereas free RTX only stabilizes intracellular TS. Again, using our previous synthetic 
efforts, we recruited the Kenner Safety-Catch resin for the construction of multiple TS-
directed ligand-based hydrophobic tag conjugates. The Safety-Catch resin was well 
suited for our efforts as the acylation at the terminal end of our RTX-EE (1b) conjugate 
was impractical under standard N→C solid phase peptide synthesis. With this resin, we 
were able to introduce compounds with active primary amines and varying degrees of 
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hydrophobicity as determined by their theoretical partition coefficients (LogP). 
Furthermore, this approach accommodated the relatively high-throughput requirements 
needed to produce complicated compounds with workable yields (60-100%) and apply 
them in high-volume manner for their biological evaluation (Table 4.3). We examined 23 
prospective hydrophobic tags (HyT) based on their LogP, low molecular weight (> 250 
amu), and whether they possessed and active primary or secondary amine. Structurally, 
we were interested in the effects of increasing HyT length (surface area) under aliphatic 
compounds, aromatic substituents with 1, 2, or 3 methylene spacers from their active 
amine, and spherical or elliptical non-aromatic compounds. 
The relatively small library was constructed through various stages of method 
development and each of the 23 HyT’s was used to generate a RTX-EE-HyT conjugate 
capable of targeting TS (Figure 4.8 and 4.12). Post synthesis, we evaluated each 
compound in triplicate fashion by monitoring their ability to inhibit cell proliferation in 
CHL-TS pJZ205 cells. We found this metric (IC50) to be the most useful as it was easily 
scaled for high-throughput analyses and could provide insight as to the potential of each 
compound.  
Based on our preliminary data, we found no correlation with the increasing 
surface area of the aliphatic HyT’s (Figure 4.12, group I) where only the shortest and 
longest aliphatic chains recorded inhibition numbers comparable to free 1b (Figure 
4.4A). The structure activity relationship (SAR) of benzylated HyT’s (Figure 4.12, group 
II and III) indicated that both chain length from the active amine to the benzene moiety 
and moderate tailoring of benzene with weak electron withdrawing groups were among 
the attributes that contributed to the inhibitory characteristics of each conjugate. The 
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remaining tags, group IV and VI, demonstrated excellent and mixed conclusions, 
respectively. Group IV consisted of the spherical non-aromatic compounds such as 
adamantane. This compound has already demonstrated potential as a hydrophobic tag, 
however, the mechanism involved relied upon the genetic assault of the targeted 
organism through the direct transfection of a stable fusion construct specifically targeted 
by the adamantly-ligand. Under our expertise, we found that the adamantyl moiety and 
two of its homologs (HyT’s 12 and 16) reported excellent inhibition values when 
compared to the parent compound 1b. Hence, group IV offered the most potential for 
further investigation toward the specific involvement of the proteasome.  
Taken together, we showed that although TS undoubtedly follows an ubiquitin-
independent pathway toward proteasomal degradation, we demonstrated the direct value 
in TS degradation through hydrophobic tagging. Unlike several other degradation 
methods, which require genetic intervention, hydrophobic tagging would allow for the 
direct targeting of TS and circumvent the stabilizing effect of RTX (or other antifolates 
with free carboxylates) to potentially promote what would likely be a concentration 
dependent reduction of intracellular TS. 
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